<SEC-DOCUMENT>0001193125-18-162050.txt : 20180514
<SEC-HEADER>0001193125-18-162050.hdr.sgml : 20180514
<ACCEPTANCE-DATETIME>20180514123502
ACCESSION NUMBER:		0001193125-18-162050
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20180514
DATE AS OF CHANGE:		20180514

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alphatec Holdings, Inc.
		CENTRAL INDEX KEY:			0001350653
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				202463898
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-224304
		FILM NUMBER:		18829540

	BUSINESS ADDRESS:	
		STREET 1:		5818 EL CAMINO REAL
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92008
		BUSINESS PHONE:		760-431-9286

	MAIL ADDRESS:	
		STREET 1:		5818 EL CAMINO REAL
		CITY:			CARLSBAD
		STATE:			CA
		ZIP:			92008
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>d571807d424b3.htm
<DESCRIPTION>424B3
<TEXT>
<HTML><HEAD>
<TITLE>424B3</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Filed Pursuant to Rule 424(b)(3) <BR>Registration No. 333-224304 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">PROSPECTUS </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g571807g73t22.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:24pt; font-family:Times New Roman" ALIGN="center"><B>ALPHATEC HOLDINGS, INC. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>36,129,060 Shares of Common Stock </B></P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus
covers the sale or other disposition from time to time of up to 36,129,060 shares of our common stock, $0.0001 par value per share (&#147;<U>Common Stock</U>&#148;), including: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">3,265,132 shares of Common Stock (the &#147;<U>Merger Closing Shares</U>&#148;) issued to certain Selling Stockholders (as defined below) in connection with that certain Agreement and Plan of Merger, dated March&nbsp;6,
2018 (the &#147;<U>Merger Agreement</U>&#148;), among the Company, SafeOp Surgical, Inc. (&#147;<U>SafeOp</U>&#148;), and certain other parties, pursuant to which SafeOp was acquired by the Company by merger (the &#147;<U>Merger</U>&#148;);
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">987,578 shares of Common Stock (the &#147;<U>Merger Note Shares</U>&#148;) issuable upon conversion of certain convertible notes of the Company issued in the Merger (the &#147;<U>Merger Notes</U>&#148;);
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,330,263 shares of Common Stock issuable to certain Selling Stockholders (the &#147;<U>Milestone Shares</U>&#148;) underlying rights to acquire Common Stock issuable upon achievement of certain post-closing milestones
in connection with the Merger; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">2,200,000 shares of Common Stock (the &#147;<U>Merger Warrant Shares</U>&#148;) issuable to certain Selling Stockholders upon exercise of certain warrants of the Company issued in the Merger (the &#147;<U>Merger
Warrants</U>&#148;); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">14,349,236 shares of Common Stock (the &#147;<U>Series B Preferred Conversion Shares</U>&#148;) issuable to certain Selling Stockholders upon conversion of shares of our Series B Convertible Preferred Stock (the
&#147;<U>Series B Preferred Stock</U>&#148;) issued to certain investors identified herein as Selling Stockholders in that certain private placement that closed on March&nbsp;8, 2018 (the &#147;<U>Private Placement</U>&#148;); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">12,196,851 shares of Common Stock (the &#147;<U>Private Placement Shares</U>&#148;) issuable to certain Selling Stockholders upon exercise of certain warrants of the Company issued in the Private Placement (the
&#147;<U>Private Placement Warrants</U>&#148;); and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">1,800,000 shares of Common Stock (the &#147;<U>New Warrant Shares</U>&#148;) issuable to a Selling Stockholder upon exercise of certain warrants of the Company (the &#147;<U>New Warrants</U>&#148;) issued or issuable
pursuant to that certain Warrant Exercise Agreement, dated March&nbsp;8, 2018 (the &#147;<U>Warrant Exercise Agreement</U>&#148;), between the Company and such Selling Stockholder (the &#147;<U>Warrant Holder</U>&#148;). </TD></TR></TABLE>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, this prospectus relates to an undetermined number of additional shares of our Common Stock issued or then issuable upon any stock
split, dividend, or other distribution, recapitalization or similar event with respect to the foregoing, that may be offered from time to time by the Selling Stockholders. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Stockholders may, from time to time, sell, transfer, or otherwise dispose of any or all of their shares of Common Stock or
interests in shares of Common Stock on any stock exchange, market, or trading facility on which the shares are traded or in private transactions. These dispositions may be at fixed prices, at prevailing market prices at the time of sale, at prices
related to the prevailing market price, at varying prices determined at the time of sale, or at negotiated prices. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Alphatec is not offering any shares of our Common Stock for sale under this prospectus. We
will not receive any of the proceeds from the sale or other disposition of the shares of our Common Stock by the Selling Stockholders, other than any proceeds from the cash exercise of the Merger Warrants, the Private Placement Warrants or the New
Warrants by the Selling Stockholders to purchase shares of our Common Stock which are registered for resale by the Selling Stockholders under this prospectus. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We have paid the fees and expenses incident to the registration of the shares of Common Stock for sale by the Selling Stockholders. Our
registration of the shares of Common Stock covered by this prospectus does not mean that the Selling Stockholders will offer or sell any of the shares. </P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock is listed on The Nasdaq Capital Market (&#147;<U>Nasdaq</U>&#148;) under the symbol &#147;ATEC.&#148; On April&nbsp;11, 2018,
the last reported sale price of our Common Stock was $3.47 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves risk. Please see &#147;<A HREF="#supptx571807_5">Risk
 Factors</A>&#148; on page 4 for a discussion of certain risks that you should consider in connection with an investment in the securities. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>We may
amend or supplement this prospectus from time to time by filing amendments or supplements as required. You should read the entire prospectus and any amendments or supplements carefully before you make your investment decision. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this
prospectus is truthful or complete. Any representation to the contrary is a criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>This
prospectus is dated May&nbsp;11, 2018. </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx571807_1">About This Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx571807_2">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx571807_3">Documents Incorporated by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx571807_4">Information Regarding Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx571807_5">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx571807_6">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx571807_7">Selling Stockholders</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx571807_8">Selling Stockholders Table</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">12</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx571807_9">Description of Capital Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx571807_10">Description of Warrants</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx571807_11">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx571807_12">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#supptx571807_13">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">26</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx571807_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> under the Securities Act of 1933, as
amended (the &#147;<U>Securities Act</U>&#148;), that we filed with the Securities and Exchange Commission (the &#147;<U>SEC</U>&#148;) using the &#147;shelf&#148; registration process. Under this shelf registration process, the Selling Stockholders
named in this prospectus may offer and sell the securities described in this prospectus in one or more offerings. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should rely only on
the information contained in or incorporated by reference into this prospectus or any accompanying prospectus supplement. Neither we nor the Selling Stockholders have authorized anyone to provide you with different information. This document may
only be used where it is legal to sell these securities. You should not assume that the information contained in this prospectus, or in any prospectus supplement, is accurate as of any date other than its date regardless of the time of delivery of
the prospectus or prospectus supplement or any sale of the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus and any accompanying prospectus supplement may
include trademarks, service marks and trade names owned by us or other companies. All trademarks, service marks and trade names included in this prospectus are the property of their respective owners. As used in this prospectus, unless the context
otherwise requires, all references to &#147;we,&#148; &#147;us,&#148; &#147;our,&#148; the &#147;Company&#148; and &#147;Alphatec,&#148; are to Alphatec Holdings, Inc., a Delaware corporation, and its subsidiaries, collectively. All references to
&#147;this prospectus&#148; refer to this prospectus and any applicable prospectus supplement, unless the context otherwise requires. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx571807_2">
</A>WHERE YOU CAN FIND MORE INFORMATION </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with
the SEC. Our SEC filings are available to the public over the Internet at the SEC&#146;s website at <I>www.sec.gov</I> and on our corporate website at <I>www.atecspine.com</I>. Information on our website does not constitute part of this prospectus.
You may inspect without charge any documents filed by us at the SEC&#146;s Public Reference Room at 100 F Street, N.E., Washington, D.C. 20549. You may obtain copies of all or any part of these materials from the SEC upon the payment of certain fees
prescribed by the SEC. Please call the SEC at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-SEC-0330</FONT></FONT></FONT> for further information on the Public Reference Room. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx571807_3"></A>DOCUMENTS INCORPORATED BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to &#147;incorporate by reference&#148; into this prospectus the information in other documents we file with the SEC, which
means that we can disclose important information to you by referring you to those documents. The information incorporated by reference is an important part of this prospectus. Some information contained in this prospectus updates the information
incorporated by reference, and information that we file subsequently with the SEC will automatically update this prospectus. In other words, in the case of a conflict or inconsistency between information set forth in this prospectus and information
that we file later and incorporate by reference into this prospectus, you should rely on the information contained in the document that was filed later. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In particular, we incorporate by reference into this prospectus the documents listed below (and any amendments thereto) and any future filings
we make with the SEC under Sections 13(a), 13(c), 14 or 15(d) of the Securities Exchange Act of 1934, as amended (&#147;<U>Exchange Act</U>&#148;), after the initial filing of the registration statement that contains this prospectus and prior to the
time that all the securities offered by this prospectus have been sold by the Selling Stockholders as described in this prospectus (other than, in each case, documents or information deemed to have been &#147;furnished&#148; and not
&#147;filed&#148; in accordance with SEC rules) or such registration statement has been withdrawn: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> or <FONT STYLE="white-space:nowrap">8-K/A</FONT> filed on March&nbsp;12, 2018, April&nbsp;16, 2018, and April 27, 2018; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2017, filed on March&nbsp;9, 2018; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our Definitive Proxy Statement filed on Schedule 14A on April&nbsp;25, 2018, relating to our Annual Meeting of Stockholders to be held May&nbsp;17, 2018; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the description of our Common Stock contained in our Registration Statement on Form <FONT STYLE="white-space:nowrap">8-A</FONT> filed pursuant to Section&nbsp;12(b) of the Exchange Act as filed with SEC on May&nbsp;26,
2006, including any subsequent amendments or reports filed for the purpose of updating such description. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any statement
contained in a document incorporated or deemed to be incorporated by reference in this prospectus will be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is
or is deemed to be incorporated by reference in this prospectus modifies or supersedes that statement. Any statement so modified or superseded will not be deemed, except as so modified or superseded, to constitute a part of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You may request a copy of the registration statement, the above filings and any future filings that are incorporated by reference into this
prospectus, other than an exhibit to a filing unless that exhibit is specifically incorporated by reference into that filing, at no cost to you, by writing or calling us at the following address: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Alphatec Holdings, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Corporate Secretary </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5818 El Camino Real </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Carlsbad, CA
92008 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(760) <FONT STYLE="white-space:nowrap">431-9286</FONT> </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as provided above, no other information, including information on our website, is incorporated by reference in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx571807_4"></A>INFORMATION REGARDING FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The information in this prospectus, including information in documents incorporated by reference in this prospectus, includes statements of
our expectations, intentions, plans and beliefs that constitute &#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the Exchange Act and are intended to come within the safe
harbor protection provided by those sections. These statements, which involve risks and uncertainties, may relate to the discussion of our business strategies and our expectations concerning future operations and business plans, our future growth
strategy, including our plans to expand, develop, or acquire particular operations or businesses, margins, profitability, trends, investing, financing activities for our future liquidity and capital resources, and to analyses and other information
that are based on forecasts of future results and estimates of amounts not yet determinable. We have used words such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expect,&#148; &#147;intend,&#148; &#147;plan,&#148;
&#147;anticipate,&#148; &#147;believe,&#148; &#147;think,&#148; &#147;estimate,&#148; &#147;seek,&#148; &#147;predict,&#148; &#147;could,&#148; &#147;project,&#148; &#147;potential,&#148; &#147;continue&#148; and other similar terms and phrases,
including references to assumptions, in this prospectus to identify forward-looking statements. These forward-looking statements are made based on expectations and beliefs concerning future events affecting us and are subject to uncertainties, risks
and factors relating to our operations and business environments, all of which are difficult to predict and many of which are beyond our control, that could cause our actual results to differ materially from those matters expressed or implied by
these forward-looking statements. Such risks and other factors include those listed in the &#147;Risk Factors&#148; incorporated by reference into this prospectus from our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K,</FONT> as
updated by subsequent reports. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">You should read this prospectus, and the documents that we reference in this prospectus and which have
been filed as exhibits to the registration statement of which this prospectus is a part, completely and with the understanding that our actual future results may be materially different from what we expect. The information contained in this
prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any issuance or sale of our common shares. Except as required by law, we do not assume any obligation to update any
forward-looking statements. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx571807_5"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Please carefully consider the risk factors described in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal
year ended December&nbsp;31, 2017 and periodic reports filed with the SEC, which are incorporated by reference in this prospectus. Before making an investment decision, you should carefully consider these risks as well as other information we
include or incorporate by reference in this prospectus or include in any applicable prospectus supplement. Additional risks and uncertainties not presently known to us or that we deem currently immaterial may also impair our business operations or
adversely affect our results of operations or financial condition. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx571807_6"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Stockholders will receive all of the net proceeds from the sale of their Common Stock under this prospectus, including the Common
Stock underlying the Series B Preferred Stock, the Merger Warrants, and the Private Placement Warrants. We will not receive any of the proceeds from the sale of the Common Stock by the Selling Stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Stockholders will pay any underwriting discounts and commissions and expenses incurred by the Selling Stockholders for brokerage,
accounting, tax, legal services or any other expenses incurred by the Selling Stockholders in disposing of these shares. We will bear all other costs, fees and expenses incurred in effecting the registration of the shares covered by this prospectus.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx571807_7"></A>SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shares Issued to Certain Selling Stockholders in the Merger </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;6, 2018, the Company and its newly-created wholly-owned subsidiary, Safari Merger Sub, Inc. (&#147;<U>Sub</U>&#148;), entered
into the Merger Agreement with SafeOp, certain key stockholders of SafeOp, and a stockholder representative. The Merger Agreement provided for the Merger, which was consummated on March&nbsp;8, 2018, in which Sub was merged into SafeOp, with SafeOp
being the surviving corporation and a wholly-owned subsidiary of the Company. Under the terms of the Merger Agreement, the Company paid to the former stockholders of SafeOp $15&nbsp;million in cash, the Merger Closing Shares, the Merger Notes that
are convertible into the Merger Shares and the Merger Warrants to purchase the Merger Warrant Shares at an exercise price of $3.50 per share. An additional 443,421 shares of Common Stock are issuable upon achievement of certain post-closing
milestones (the &#147;<U>First Milestone Merger Shares</U>&#148;), and 886,842 shares of Common Stock are issuable upon achievement of certain additional post-closing milestones (the &#147;<U>Second Milestone Merger Shares</U>&#148;). The Merger
Closing Shares, Merger Note Shares, Merger Warrant Shares, First Milestone Merger Shares, and Second Milestone Merger Share are referred to collectively as the &#147;<U>Merger Shares</U>.&#148; The closing of the Merger (the
&#147;<U>Closing</U>&#148;) occurred simultaneous with the closing and funding of the Private Placement described below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Prior to the
Merger there were no material relationships between the Company and SafeOp or any affiliates of the Company and SafeOp. The Merger Agreement contains customary representations, warranties and covenants by SafeOp and the Company, as well as customary
indemnification provisions among the parties. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shares Issued to Certain Selling Stockholders in the Private Placement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;8, 2018, the Company entered into a securities purchase agreement (the &#147;<U>Securities Purchase Agreement</U>&#148;) pursuant
to which the Company sold in the Private Placement to certain institutional and accredited investors (collectively, the &#147;<U>Purchasers</U>&#148;), including certain directors and executive officers of the Company, at a purchase price of $1,000
per share, 45,200 shares (the &#147;<U>Series B Preferred Shares</U>&#148;) of its newly designated Series B Preferred Stock, and the Private Placement Warrants to purchase the Private Placement Warrant Shares at an exercise price of $3.50 per
share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series B Preferred Shares will be converted automatically into the Series B Preferred Conversion Shares at a conversion price
of $3.15 per share (subject to adjustment as described below and in the Series B Designation of Rights (as defined below)) upon approval by the Company&#146;s stockholders (the &#147;<U>Stockholder Approval</U>&#148;) at the 2018 Annual Meeting of
Stockholders as required in accordance with the Nasdaq rules described below. The Private Placement Warrants will become exercisable following Stockholder Approval, are subject to certain ownership limitations in certain cases, and expire five years
after the date of the Stockholder Approval. The Series B Preferred Conversion Shares and the Private Placement Warrant Shares are referred to collectively as the &#147;<U>Private Placement Shares</U>.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The aggregate gross proceeds from the Private Placement were $45.2&nbsp;million. The Company used a portion of the Private Placement proceeds
to fund the cash consideration paid in the Merger. The Company intends to use the balance of the net proceeds from the Private Placement for general corporate and working capital purposes, and to fund additional strategic initiatives. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights and preferences of the Series B Preferred Stock are designated by the Company&#146;s Board of Directors in the Certificate of
Designation of Preferences, Rights, and Limitations of the Series B Preferred Stock of Alphatec Holdings, Inc. (the &#147;<U>Series B Designation of Rights</U>&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each share of Series B Preferred Stock has $0.0001 par value per share and a stated value of $1,000, with the aggregate stated value of all
shares of Series B Preferred Stock being $45.2&nbsp;million. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series B Preferred Stock will be entitled to dividends on an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-if-converted</FONT></FONT> basis in the same form as any dividends actually paid on shares of Common Stock or other securities. In addition, until the earlier of the date there are no
shares of Series B Preferred Stock outstanding, or one year from the effective date of this registration statement, the conversion price in respect of the Series B Preferred Stock is also subject to anti-dilution protection adjustment in the event
the Company issues securities at an effective price less than the initial conversion price thereof, subject to certain exceptions. If the Stockholder Approval is not obtained, the shares of Series B Preferred Stock will not become convertible, and
will remain outstanding in accordance with the terms of the Series B Designation of Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise required by law, the
holders of Series B Preferred Stock will have no right to vote on matters submitted to a vote of the Company&#146;s stockholders. Without the prior written consent of 75% of the outstanding shares of Series B Preferred Stock, however, the Company
may not: (a)&nbsp;alter or change adversely the powers, preferences or rights given to the Series B Preferred Stock or alter or amend the Series B Designation of Rights; (b)&nbsp;amend the Company&#146;s certificate of incorporation or other charter
documents in any manner that adversely affects any rights of the holders of Series B Preferred Stock; (c)&nbsp;increase the number of authorized shares of Series B Preferred Stock; or (d)&nbsp;enter into any agreement with respect to any of the
foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of the dissolution and winding up of the Company, the proceeds available for distribution to the Company&#146;s
stockholders shall be distributed <I>pari passu</I> among the holders of the shares of Common Stock and Series B Preferred Stock, pro rata based upon the number of shares held by each such holder, as if the outstanding shares of Series B Preferred
Stock were converted into shares of Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Shares Issued to a Selling Stockholder in Connection with the Warrant Exercise Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">On March&nbsp;8, 2018, the Company entered into the Warrant Exercise Agreement with the Warrant Holder to purchase up to an aggregate of
2.4&nbsp;million shares of Common Stock, at an exercise price of $2.00 per share (the &#147;<U>Original Warrant</U>&#148;). Pursuant to the terms of the Warrant Exercise Agreement, the Warrant Holder agreed to exercise, from time to time and in
accordance with the terms of the Original Warrant, including certain beneficial ownership limitations set forth therein, the Original Warrant for cash (the &#147;<U>Warrant Exercise</U>&#148;). As a result of the Warrant Exercise, the Company
received gross proceeds of $3.4&nbsp;million on March&nbsp;8, 2018 from the exercise of 1.7&nbsp;million shares under the Original Warrant, and expects to receive additional gross proceeds of up to $1.4&nbsp;million thereafter from additional
exercises of the remaining shares under the Original Warrant following Stockholder Approval. The Company expects to use the net proceeds from the exercise of the Original Warrant for general corporate and working capital purposes and to fund
strategic initiatives. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pursuant to the terms of the Warrant Exercise Agreement, and in order to induce the Warrant Holder to exercise the
Original Warrant, the Company issued the New Warrants to the Warrant Holder. The New Warrants entitle the Warrant Holder to purchase a number of shares of Common Stock equal to 75% of the number of shares of Common Stock received by the Warrant
Holder upon the full cash exercise of the Original Warrant (i.e., 75% of 2,400,000 shares of Common Stock, or 1,800,000 shares of Common Stock). The terms of the New Warrants are substantially similar to the terms of the Private Placement Warrants,
and have an exercise price of $3.50 per share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The New Warrants will become exercisable following Stockholder Approval, are subject to
certain ownership limitations, and expire five years after the date of Stockholder Approval. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registration Rights Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the Private Placement, the Merger, and the Warrant Exercise Agreement, the Company entered into a registration rights
agreement (as amended, the &#147;<U>Registration Rights Agreement</U>&#148;) with the Purchasers, the former stockholders of SafeOp, and the Warrant Holder (collectively, the &#147;<U>Holders</U>&#148;), effective as of the Closing. Pursuant to the
Registration Rights Agreement, the Company agreed to prepare and file a </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
registration statement with the SEC (the &#147;<U>Resale Registration Statement</U>&#148;) by April&nbsp;16, 2018 for purposes of registering the resale of the Private Placement Shares, the
Merger Shares, and the New Warrant Shares. This prospectus is part of the Resale Registration Statement filed in furtherance of our obligations under the Registration Rights Agreement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Support Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with
the Private Placement, the Merger and the Warrant Exercise Agreement, certain stockholders of the Company then comprising a majority of the outstanding shares of Common Stock entered into support agreements (the &#147;<U>Support
Agreements</U>&#148;) pursuant to which such stockholders agreed to vote all shares of Common Stock owned by them in favor of the Company&#146;s issuances of the Merger Shares in connection with the Merger, Private Placement Shares in connection
with the Private Placement, and New Warrant Shares in connection with the New Warrants. Accordingly, a sufficient number of stockholders signed the Support Agreements to ensure approval of the Company&#146;s issuance of the Merger Shares in
connection with the Merger, the Private Placement Shares in connection with the Private Placement, and the New Warrant Shares in connection with the New Warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stockholder Approval Requirements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
Company&#146;s issuances of Merger Shares, Private Placement Shares and New Warrant Shares are subject to the Stockholder Approval requirements summarized below. Until we have obtained Stockholder Approval, we will not issue Merger Shares, Private
Placement Shares or New Warrant Shares in excess of 19.9% of the issued and outstanding shares of Common Stock of the Company prior to the Merger and Private Placement. Also, until Stockholder Approval has been obtained, the Company will not issue
any Private Placement Shares to any &#147;<U>Insiders</U>&#148; of the Company (officers, directors, employees, consultants), at prices less than the fair market value of the Company&#146;s Common Stock. Accordingly, the Company will not issue any
Merger Note Shares, Second Milestone Shares, Merger Warrant Shares, Series B Conversion Shares, Private Placement Warrant Shares or New Warrant Shares until we have obtained Stockholder Approval. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our Common Stock is listed on The Nasdaq Capital Market (&#147;<U>Nasdaq</U>&#148;) and we are subject to the Nasdaq Listing Rules
(&#147;<U>Nasdaq Rules</U>&#148;) governing listing requirements (Section 5500 of the Nasdaq Rules for securities listed on the Capital Market) and corporate governance (Section 5600 of the Nasdaq Rules) of companies with securities listed on
Nasdaq. Pursuant to the terms of both the Merger Agreement and the Securities Purchase Agreement, we have covenanted to obtain approval of our stockholders as may be required by the Nasdaq Rules. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nasdaq Rules 5635(a), (b) and (d), apply to the issuance of shares of our Common Stock (or securities convertible into or exercisable for
Common Stock): </P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(A) representing more than 19.99% of the outstanding Common Stock or voting power of the Company in connection with:
(i)&nbsp;the acquisition of SafeOp pursuant to the Merger; (ii)&nbsp;the Company&#146;s issuance of shares of Common Stock upon the conversion of the of Series B Preferred Stock and related exercise of the Private Placement Warrants; and
(iii)&nbsp;the Company&#146;s issuance of shares of Common Stock upon the exercise of the New Warrants; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(B) in connection with the
Securities Purchase Agreement to Insiders at less than market prices; and </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">(C) in connection with the Merger, the Securities Purchase
Agreement and the Warrant Exercise Agreement that could result in a Nasdaq Change in Control. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Common Stock issuances referred to in
(A)&nbsp;through (C) above would occur with respect to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the conversion of the Merger Notes, the exercise of the Merger Warrants, and the potential issuance of the Second Milestone Merger Shares, all in connection with the Merger; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the automatic conversion of the Series B Preferred Stock and the exercise of the Private Placement Warrants in connection with the Private Placement; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the exercise of the New Warrants. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nasdaq Listing Rule 5635(a) (the &#147;<U>20% Acquisition
Rule</U>&#148;) requires that an issuer obtain stockholder approval prior to the issuance of common stock in connection with the acquisition of the stock or assets of another company if, due to the present or potential issuance of common stock,
including shares issued pursuant to an <FONT STYLE="white-space:nowrap">earn-out</FONT> provision or similar type of provision, or securities convertible into or exercisable for common stock: (i)&nbsp;the common stock has or will have upon issuance
voting power equal to or in excess of 20% of the voting power outstanding before the issuance of stock or securities convertible into or exercisable for common stock; or (ii)&nbsp;the number of shares of common stock to be issued is or will be equal
to or in excess of 20% of the number of shares of common stock outstanding before the issuance of the stock or securities. The issuance of the Merger Closing Shares, and the potential issuance of the First Milestone Merger Shares, represent
issuances by the Company of less than 19.99% of our issued and outstanding Common Stock, and thus could be effected prior to and without Stockholder Approval. However, for purposes of analyzing application of the Nasdaq stockholder approval rules,
and compliance with Nasdaq Rule 5635(a) in particular, the Company is aggregating the Merger Shares, the Private Placement Shares and the New Warrant Shares. The proceeds from the sale of the Series B Preferred Stock and the Private Placement
Warrants were used, in part, to finance the Merger, and the Merger Shares were issued as part of the consideration paid to the former stockholders of SafeOp in connection with the Merger. Thus, the conversion of the Merger Notes, the exercise of the
Merger Warrants and the potential issuance of the Second Milestone Merger Shares (all in connection with the Merger), the automatic conversion of the Series B Preferred Stock and the exercise of the Private Placement Warrants in connection with the
Private Placement, and the exercise of the New Warrants will result in the issuance of our Common Stock representing in excess of 20% of the voting power, and 20% of the number of shares of our Common Stock, in each case, outstanding, before the
Merger and the Private Placement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nasdaq Listing Rule 5635(d) (the &#147;<U>20% Private Placement Rule</U>&#148;) requires that an issuer
obtain stockholder approval prior to the issuance of common stock if such issuance is for less than the greater of book or market value of the common stock and would equal 20% or more of the common stock or voting power of the issuer outstanding
before the issuance. The conversion price of the Series B Preferred Stock is less than the greater of the book or market value of our Common Stock immediately before we entered into the Securities Purchase Agreement. In addition, the terms of the
Series B Preferred Stock and the Securities Purchase Agreement include anti-dilution adjustments that could result in a reduction of the conversion price, or the issuance of additional shares of Common Stock, in the future. Furthermore, the issuance
of our Common Stock upon conversion of the Series B Preferred Stock and exercise of the Private Placement Warrants will exceed 20% of our Common Stock currently outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nasdaq Listing Rule 5635(c) (the &#147;<U>Insider Equity Compensation Rule</U>&#148;) requires that we obtain stockholder approval prior to
issuing shares of common stock to Insiders of the Company at less than market price, including issuance of our Common Stock upon conversions of the Series B Preferred Stock at the current conversion price of $3.15 per share, and potential
anti-dilution issuances of Common Stock to any such Insiders pursuant to the provisions of the Securities Purchase Agreement. Accordingly, Stockholder Approval will include approval at the Company&#146;s Annual Meeting to issue the Series B
Preferred Conversion Shares, the Private Placement Warrant Shares, and shares of Common Stock pursuant to any anti-dilution protection provisions of the Securities Purchase Agreement or Series B Designation of Rights, to Insiders of the Company,
when Common Stock is issued in such transactions at less than market value. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, Nasdaq Listing Rule 5635(b) requires prior
stockholder approval for issuances of securities that could result in a &#147;change of control&#148; of the issuer (the &#147;<U>Change of Control Rule</U>&#148;). Nasdaq may deem a change of control to occur when, as a result of an issuance, an
investor or a group would own, or have the right to acquire, 20% or more of the outstanding shares of common stock or voting power, and such ownership or voting power of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
an issuer would be the largest ownership position of the issuer (a &#147;<U>Nasdaq Change of Control</U>&#148;). Upon securing Stockholder Approval and triggering the automatic conversion of the
Series B Preferred Stock, <FONT STYLE="white-space:nowrap">L-5</FONT> Healthcare Partners, LLC (&#147;<U><FONT STYLE="white-space:nowrap">L-5</FONT> Healthcare</U>&#148;), as the lead purchaser in the Private Placement, would own in excess of 20% of
the outstanding shares of Common Stock or voting power of the Company. Stockholder Approval is necessary to satisfy the requirements of the Change of Control Rule, as that rule would be triggered by the issuance of Common Stock to <FONT
STYLE="white-space:nowrap">L-5</FONT> Healthcare upon conversion of its Series B Preferred Stock and the exercise of its Private Placement Warrants. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Selling Stockholders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus
covers the public resale of the shares of Common Stock owned or to be acquired by the Purchasers in connection with the Private Placement, by the former SafeOp stockholders in connection with the Merger, and by the Warrant Holder listed in the table
below as the selling stockholders (together with their transferees, pledgees, donees, or successors, the &#147;<U>Selling Stockholders</U>&#148;). The Selling Stockholders may from time to time offer and sell pursuant to this prospectus any or all
of the shares of Common Stock owned by them identified in the table. The Selling Stockholders may sell some, all or none of the shares covered by this prospectus, and they and we make no representation that the shares will be offered for sale. The
table below presents information regarding the Selling Stockholders and the shares that they may offer and sell from time to time under this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following table sets forth: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of shares of Common Stock beneficially owned by the Selling Stockholders prior to the sale of the shares covered by this prospectus; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of shares of Common Stock that may be offered by the Selling Stockholders pursuant to this prospectus; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of shares of Common Stock to be beneficially owned by the Selling Stockholders and their affiliates following the sale of any shares covered by this prospectus; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the percentage of our issued and outstanding Common Stock to be beneficially owned by the Selling Stockholders and their affiliates following the sale of all shares owned by the particular Selling Stockholder covered by
this prospectus. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">All information with respect to Common Stock ownership of the Selling Stockholders has been furnished by
or on behalf of the Selling Stockholders and is as of April&nbsp;11, 2018. We believe, based on information supplied by the Selling Stockholders, that except as may otherwise be indicated in this section, each of the Selling Stockholders and its
affiliates identified herein have sole voting and dispositive power with respect to the Common Stock reported as beneficially owned by it. Because the Selling Stockholders may sell some or all of the shares included in this prospectus, and because
there are currently no agreements, arrangements or understandings with respect to the sale of any of the shares, no estimate can be given as to the number of shares available for resale hereby that will be held by the Selling Stockholders in the
future. In addition, the Selling Stockholders may have sold, transferred or otherwise disposed of, or may sell, transfer or otherwise dispose of, at any time and from time to time, the Common Stock they hold in transactions exempt from the
registration requirements of the Securities Act after the date on which it provided the information set forth on the table below. We have, therefore, assumed for the purposes of the following table, that each Selling Stockholder will sell all of the
shares owned beneficially by it listed in the table below that are covered by this prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under the terms of the Private Placement
Warrants and the New Warrants, the Selling Stockholders, unless they elect otherwise, may not exercise the Private Placement Warrants or the New Warrants to the extent such exercise would cause the Selling Stockholder, together with its affiliates
and attribution parties, to beneficially own a number of shares of Common Stock which would exceed the applicable beneficial ownership limitation set forth therein (4.99% or, at the election of the holder, 9.99%) (the &#147;<U>Beneficial Ownership
Limitation</U>&#148;), </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
excluding for purposes of such determination shares of Common Stock issuable upon exercise of the Private Placement Warrants or the New Warrants which have not been exercised. However, the number
of shares in the second column of the table below assumes full exercise of the Private Placement Warrants and the New Warrants held by the Selling Stockholders, and does not reflect the application of the Beneficial Ownership Limitation to the
exercise of the Private Placement Warrants and the New Warrants as set forth in this paragraph. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The third column of the table lists the
shares of Common Stock being offered by this prospectus by the Selling Stockholders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In accordance with the terms of the Registration
Rights Agreement with the Selling Stockholders, this prospectus generally covers the resale of the sum of (i)&nbsp;the Merger Closing Shares, (ii)&nbsp;the Merger Note Shares, (iii)&nbsp;the Milestone Shares, (iv)&nbsp;the Merger Warrant Shares,
without regard to any limitations on the exercise of the Merger Warrants, (v)&nbsp;the Series B Conversion Preferred Shares, (vi)&nbsp;the Private Placement Warrant Shares, without regard to any limitations on the exercise of the Private Placement
Warrants, (vii)&nbsp;the New Warrant Shares, without regard to any limitations on the exercise of the New Warrants and (viii)&nbsp;an indeterminate number of additional shares of Common Stock issued or then issuable upon any stock split, dividend,
or other distribution, recapitalization or similar event with respect to the forgoing. The Selling Stockholders may sell all, some or none of their shares in this offering. See &#147;Plan of Distribution,&#148; below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Beneficial ownership for the purposes of the table is determined in accordance with the rules and regulations of the SEC. The SEC rules
regarding beneficial ownership determination generally provide that a person is the &#147;beneficial owner&#148; of securities if such person has or shares the power to vote or direct the voting thereof, or to dispose or direct the disposition
thereof, or has the right to acquire such powers within 60 days. At our 2018 Annual Meeting of Stockholders, we are seeking Stockholder Approval of the issuance of Merger Note Shares, Milestone Shares, Merger Warrant Shares, Series B Preferred
Conversion Shares, Private Placement Warrant Shares and New Warrant Shares, all as described above. Certain stockholders of the Company comprising a majority of the outstanding shares of Common Stock entered into the Support Agreement in connection
with the Merger the Private Placement and the Warrant Exercise Agreement as describe above. However, notwithstanding the Support Agreements, we cannot determine with certainty at this time whether, or if, Stockholder Approval will be secured within
60 days of the date of this registration statement. For purposes only of the table calculations presented below, we assume that the Company will secure the Stockholder Approval, and that the Selling Stockholders are therefore the beneficial owners
of all Merger Shares, Private Placement Shares and New Warrant Shares. Except as disclosed in the table, we believe that the Selling Stockholders and their affiliates identified herein possess sole voting and investment power over all shares of
Common Stock shown as beneficially owned by such Selling Stockholders and affiliates. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx571807_8"></A>SELLING STOCKHOLDERS TABLE </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="44%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Name of Selling</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number<BR>of Shares of<BR>Common&nbsp;Stock<BR>Beneficially<BR>Owned Prior<BR>to this<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number<BR>of Shares of<BR>Common&nbsp;Stock<BR>Available<BR>Pursuant<BR>to this<BR>Prospectus</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number<BR>of&nbsp;Shares&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Common<BR>Stock<BR>Beneficially<BR>Owned<BR>After Sale<BR>of Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Percent of<BR>Outstanding<BR>Common<BR>Stock<BR>Beneficially<BR>Owned<BR>After Sale<BR>of Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tullis Dickerson Capital Focus III, LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,021,651</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,021,651</TD>
<TD NOWRAP VALIGN="bottom">(1)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tullis Growth Fund, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,057,065</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,057,065</TD>
<TD NOWRAP VALIGN="bottom">(2)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Snow</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228,986</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228,986</TD>
<TD NOWRAP VALIGN="bottom">(3)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Richard O&#146;Brien</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228,986</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">228,986</TD>
<TD NOWRAP VALIGN="bottom">(4)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lighthouse Holdings Corporation</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">707,321</TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">707,321</TD>
<TD NOWRAP VALIGN="bottom">(5)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eugene Santa Cattarina</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">314,253</TD>
<TD NOWRAP VALIGN="bottom">(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">314,253</TD>
<TD NOWRAP VALIGN="bottom">(6)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Christopher Brown</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,365</TD>
<TD NOWRAP VALIGN="bottom">(7)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,365</TD>
<TD NOWRAP VALIGN="bottom">(7)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark D&#146;Addato</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,833</TD>
<TD NOWRAP VALIGN="bottom">(8)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">96,833</TD>
<TD NOWRAP VALIGN="bottom">(8)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">James L.L. Tullis</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,429</TD>
<TD NOWRAP VALIGN="bottom">(9)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">114,429</TD>
<TD NOWRAP VALIGN="bottom">(9)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Bulger Partners</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275,327</TD>
<TD NOWRAP VALIGN="bottom">(10)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">275,327</TD>
<TD NOWRAP VALIGN="bottom">(10)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael Russell</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,850</TD>
<TD NOWRAP VALIGN="bottom">(11)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,850</TD>
<TD NOWRAP VALIGN="bottom">(11)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jim Russell</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,850</TD>
<TD NOWRAP VALIGN="bottom">(12)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">18,850</TD>
<TD NOWRAP VALIGN="bottom">(12)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Zachary Levine</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,504</TD>
<TD NOWRAP VALIGN="bottom">(13)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,504</TD>
<TD NOWRAP VALIGN="bottom">(13)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Warren Eng</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,504</TD>
<TD NOWRAP VALIGN="bottom">(14)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,504</TD>
<TD NOWRAP VALIGN="bottom">(14)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Curt LaBelle</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,860</TD>
<TD NOWRAP VALIGN="bottom">(15)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,860</TD>
<TD NOWRAP VALIGN="bottom">(15)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tsontcho Ianchulev</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,416</TD>
<TD NOWRAP VALIGN="bottom">(16)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4,416</TD>
<TD NOWRAP VALIGN="bottom">(16)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Donald Charney</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,669</TD>
<TD NOWRAP VALIGN="bottom">(17)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,669</TD>
<TD NOWRAP VALIGN="bottom">(17)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Murkin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,741</TD>
<TD NOWRAP VALIGN="bottom">(18)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,741</TD>
<TD NOWRAP VALIGN="bottom">(18)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John Shambroom</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,681</TD>
<TD NOWRAP VALIGN="bottom">(19)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,681</TD>
<TD NOWRAP VALIGN="bottom">(19)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Daniel Stashuk</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,561</TD>
<TD NOWRAP VALIGN="bottom">(20)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,561</TD>
<TD NOWRAP VALIGN="bottom">(20)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">M. Reza Kharrazi, MD</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,633</TD>
<TD NOWRAP VALIGN="bottom">(21)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,633</TD>
<TD NOWRAP VALIGN="bottom">(21)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Thomas J. Neff</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,609</TD>
<TD NOWRAP VALIGN="bottom">(22)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">55,609</TD>
<TD NOWRAP VALIGN="bottom">(22)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew L. Kahn</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,804</TD>
<TD NOWRAP VALIGN="bottom">(23)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,804</TD>
<TD NOWRAP VALIGN="bottom">(23)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">William C. Weldon</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,024</TD>
<TD NOWRAP VALIGN="bottom">(24)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">139,024</TD>
<TD NOWRAP VALIGN="bottom">(24)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Matthew Motley</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,804</TD>
<TD NOWRAP VALIGN="bottom">(25)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27,804</TD>
<TD NOWRAP VALIGN="bottom">(25)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Corsema LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,243</TD>
<TD NOWRAP VALIGN="bottom">(26)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,243</TD>
<TD NOWRAP VALIGN="bottom">(26)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Niraj A. Gupta</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,622,469</TD>
<TD NOWRAP VALIGN="bottom">(27)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">555,000</TD>
<TD NOWRAP VALIGN="bottom">(27)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,067,469</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.7</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Sabby Volatility Warrant Master Fund,&nbsp;Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,687,525</TD>
<TD NOWRAP VALIGN="bottom">(28)(29)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">687,525</TD>
<TD NOWRAP VALIGN="bottom">(29)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Broadfin Healthcare Master Fund, Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,055,557</TD>
<TD NOWRAP VALIGN="bottom">(30)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,055,557</TD>
<TD NOWRAP VALIGN="bottom">(30)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Stonepine Capital, L.P.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,761,905</TD>
<TD NOWRAP VALIGN="bottom">(31)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,761,905</TD>
<TD NOWRAP VALIGN="bottom">(31)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><FONT STYLE="white-space:nowrap">L-5</FONT> Healthcare Partners, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,682,540</TD>
<TD NOWRAP VALIGN="bottom">(32)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">14,682,540</TD>
<TD NOWRAP VALIGN="bottom">(32)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Woods 1994 Family Partnership</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,174,604</TD>
<TD NOWRAP VALIGN="bottom">(33)(34)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,174,604</TD>
<TD NOWRAP VALIGN="bottom">(34)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,000,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.6</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mortimer Berkowitz III</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,284,833</TD>
<TD NOWRAP VALIGN="bottom">(35)(36)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234,922</TD>
<TD NOWRAP VALIGN="bottom">(36)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,049,911</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Porcupine Investment Partners, LLC(37)</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">634,922</TD>
<TD NOWRAP VALIGN="bottom">(38)(39)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234,922</TD>
<TD NOWRAP VALIGN="bottom">(39)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">400,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Patrick S. Miles</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2,414,737</TD>
<TD NOWRAP VALIGN="bottom">(40)(41)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">587,303</TD>
<TD NOWRAP VALIGN="bottom">(41)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,827,434</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Terry Rich</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">822,996</TD>
<TD NOWRAP VALIGN="bottom">(42)(43)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">186,175</TD>
<TD NOWRAP VALIGN="bottom">(43)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">636,821</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IRA Resources FBO Terry Rich</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,477</TD>
<TD NOWRAP VALIGN="bottom">(44)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">107,477</TD>
<TD NOWRAP VALIGN="bottom">(44)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Craig Hunsaker</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">932,997</TD>
<TD NOWRAP VALIGN="bottom">(45)(46)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">293,652</TD>
<TD NOWRAP VALIGN="bottom">(46)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">639,345</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1.0</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Michael T. Dendinger</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,985</TD>
<TD NOWRAP VALIGN="bottom">(47)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">46,985</TD>
<TD NOWRAP VALIGN="bottom">(47)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Brian Snider</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">203,919</TD>
<TD NOWRAP VALIGN="bottom">(48)(49)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,732</TD>
<TD NOWRAP VALIGN="bottom">(49)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">145,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Scott Lish</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,367</TD>
<TD NOWRAP VALIGN="bottom">(50)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,367</TD>
<TD NOWRAP VALIGN="bottom">(50)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Tyson Marshall</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,211</TD>
<TD NOWRAP VALIGN="bottom">(51)(52)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,493</TD>
<TD NOWRAP VALIGN="bottom">(52)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9,718</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Luiz Pimenta</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">587,301</TD>
<TD NOWRAP VALIGN="bottom">(53)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">587,303</TD>
<TD NOWRAP VALIGN="bottom">(53)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="46%"></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="9%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>

<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:8pt">
<TD VALIGN="bottom"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman"><B>Name of Selling</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman"><B>Stockholders</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number<BR>of Shares of<BR>Common&nbsp;Stock<BR>Beneficially<BR>Owned Prior<BR>to this<BR>Offering</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Number<BR>of Shares of<BR>Common&nbsp;Stock<BR>Available<BR>Pursuant<BR>to this<BR>Prospectus</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Number<BR>of&nbsp;Shares&nbsp;of</B></P>
<P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:Times New Roman" ALIGN="center"><B>Common<BR>Stock<BR>Beneficially<BR>Owned<BR>After Sale<BR>of Shares</B></P></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center"><B>Percent of<BR>Outstanding<BR>Common<BR>Stock<BR>Beneficially<BR>Owned<BR>After Sale<BR>of Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lance Denardin</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138,750</TD>
<TD NOWRAP VALIGN="bottom">(54)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">138,750</TD>
<TD NOWRAP VALIGN="bottom">(54)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Gregory L. Rhinehart</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">41,622</TD>
<TD NOWRAP VALIGN="bottom">(55)(56)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">24,668</TD>
<TD NOWRAP VALIGN="bottom">(56)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">16,934</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">IRA Resources FBO Jeffrey G. Black</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">130,552</TD>
<TD NOWRAP VALIGN="bottom">(57)(58)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,367</TD>
<TD NOWRAP VALIGN="bottom">(58)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,187</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jon Allen</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">326,242</TD>
<TD NOWRAP VALIGN="bottom">(59)(60)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,367</TD>
<TD NOWRAP VALIGN="bottom">(60)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">296,875</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Lukpartners, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">396,827</TD>
<TD NOWRAP VALIGN="bottom">(61)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,827</TD>
<TD NOWRAP VALIGN="bottom">(61)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mital Sheth</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">113,414</TD>
<TD NOWRAP VALIGN="bottom">(62)(63)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">73,414</TD>
<TD NOWRAP VALIGN="bottom">(63)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Joan W. Rosenfeld Trust F/B/O Lawrence W. Rosenfeld, Lawrence W. Rosenfeld Trustee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,732</TD>
<TD NOWRAP VALIGN="bottom">(64)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,732</TD>
<TD NOWRAP VALIGN="bottom">(64)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Hammana Partners LP</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,732</TD>
<TD NOWRAP VALIGN="bottom">(65)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,732</TD>
<TD NOWRAP VALIGN="bottom">(65)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">BLR Partners</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">623,601</TD>
<TD NOWRAP VALIGN="bottom">(66)(67)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">296,000</TD>
<TD NOWRAP VALIGN="bottom">(67)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">327,601</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Yves Istel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">476,000</TD>
<TD NOWRAP VALIGN="bottom">(68)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">296,000</TD>
<TD NOWRAP VALIGN="bottom">(68)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">180,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Robert Katz</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">39,367</TD>
<TD NOWRAP VALIGN="bottom">(69)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,367</TD>
<TD NOWRAP VALIGN="bottom">(69)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">David B. Salb Trust UAD 3/28/2014, David B Salb, Trustee</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">201,750</TD>
<TD NOWRAP VALIGN="bottom">(70)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">101,750</TD>
<TD NOWRAP VALIGN="bottom">(70)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Vishal Ghiya</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205,557</TD>
<TD NOWRAP VALIGN="bottom">(71)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">205,557</TD>
<TD NOWRAP VALIGN="bottom">(71)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samir K. Patel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">484,922</TD>
<TD NOWRAP VALIGN="bottom">(72)(73)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">234,922</TD>
<TD NOWRAP VALIGN="bottom">(73)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">250,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Amit M. Patel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">346,827</TD>
<TD NOWRAP VALIGN="bottom">(74)(75)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">146,827</TD>
<TD NOWRAP VALIGN="bottom">(75)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Peter Popjevalo</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">85,923</TD>
<TD NOWRAP VALIGN="bottom">(76)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">52,858</TD>
<TD NOWRAP VALIGN="bottom">(76)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33,065</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Andrew Haber</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,462</TD>
<TD NOWRAP VALIGN="bottom">(77)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,462</TD>
<TD NOWRAP VALIGN="bottom">(77)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Kantilal K. Patel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">376,192</TD>
<TD NOWRAP VALIGN="bottom">(78)(79)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">176,192</TD>
<TD NOWRAP VALIGN="bottom">(79)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Manish K. Patel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">390,874</TD>
<TD NOWRAP VALIGN="bottom">(80)(81)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">190,874</TD>
<TD NOWRAP VALIGN="bottom">(81)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">200,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">John P. Curtin, Jr.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">217,462</TD>
<TD NOWRAP VALIGN="bottom">(82)(83)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,462</TD>
<TD NOWRAP VALIGN="bottom">(83)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">100,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Jean-Paul Weber</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,732</TD>
<TD NOWRAP VALIGN="bottom">(84)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,732</TD>
<TD NOWRAP VALIGN="bottom">(84)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Blackfin Funds Inc.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">197,462</TD>
<TD NOWRAP VALIGN="bottom">(85)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">117,462</TD>
<TD NOWRAP VALIGN="bottom">(85)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Neal Wadhera</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30,158</TD>
<TD NOWRAP VALIGN="bottom">(86)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">23,492</TD>
<TD NOWRAP VALIGN="bottom">(86)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,666</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Samit Patel</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,367</TD>
<TD NOWRAP VALIGN="bottom">(87)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">29,367</TD>
<TD NOWRAP VALIGN="bottom">(87)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">J&nbsp;&amp; B Device and Equipment, LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,097</TD>
<TD NOWRAP VALIGN="bottom">(88)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">88,097</TD>
<TD NOWRAP VALIGN="bottom">(88)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Abdel Zaharan</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,732</TD>
<TD NOWRAP VALIGN="bottom">(89)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,732</TD>
<TD NOWRAP VALIGN="bottom">(89)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&#151;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Milan Kalawadia</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">80,732</TD>
<TD NOWRAP VALIGN="bottom">(90)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,732</TD>
<TD NOWRAP VALIGN="bottom">(90)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">22,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Mark Ojeda</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">62,032</TD>
<TD NOWRAP VALIGN="bottom">(91)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">58,732</TD>
<TD NOWRAP VALIGN="bottom">(91)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">3,300</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Eric Sokolowski</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">255,557</TD>
<TD NOWRAP VALIGN="bottom">(92)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">220,150</TD>
<TD NOWRAP VALIGN="bottom">(92)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">35,407</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">*&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman">Armistice Capital Master Fund Ltd.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6,850,000</TD>
<TD NOWRAP VALIGN="bottom">(93)(94)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1,800,000</TD>
<TD NOWRAP VALIGN="bottom">(94)&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5,050,000</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7.9</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(*)</TD>
<TD ALIGN="left" VALIGN="top">Less than 1% of issued and outstanding shares beneficially owned. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">Includes 1,239,985 Merger Closing Shares, 395,902 Merger Note Shares, 503,818 Milestone Shares and 881,946 Merger Warrant Shares. James L.L. Tullis controls the general partner of Tullis Dickerson Capital Focus III, LP
and therefore may be deemed to beneficially own the shares held by Tullis Dickerson Capital Focus III, LP. Mr.&nbsp;Tullis disclaims beneficial ownership of such shares except to the extent of his pecuniary interest in such shares.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(2)</TD>
<TD ALIGN="left" VALIGN="top">Includes 900,734 Merger Closing Shares, 287,586 Merger Note Shares, 228,094 Milestone Shares and 640,651 Merger Warrant Shares. James L.L. Tullis controls the general partner of Tullis Growth Fund, L.P. and therefore
may be deemed to beneficially own the shares held by Tullis Growth Fund, L.P. Mr.&nbsp;Tullis disclaims beneficial ownership of such shares except to the extent of his pecuniary interest in such shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(3)</TD>
<TD ALIGN="left" VALIGN="top">Includes 81,309 Merger Closing Shares, 25,777 Merger Note Shares, 64,477 Milestone Shares and 57,423 Merger Warrant Shares. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(4)</TD>
<TD ALIGN="left" VALIGN="top">Includes 81,309 Merger Closing Shares, 25,777 Merger Note Shares, 64,477 Milestone Shares and 57,423 Merger Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(5)</TD>
<TD ALIGN="left" VALIGN="top">Includes 303,442 Merger Closing Shares, 96,882 Merger Note Shares, 91,172 Milestone Shares and 215,825 Merger Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(6)</TD>
<TD ALIGN="left" VALIGN="top">Includes 98,350 Merger Closing Shares, 30,993 Merger Note Shares, 115,864 Milestone Shares and 69,046 Merger Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(7)</TD>
<TD ALIGN="left" VALIGN="top">Includes 20,728 Merger Closing Shares, 6,547 Merger Note Shares, 20,507 Milestone Shares and 14,583 Merger Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(8)</TD>
<TD ALIGN="left" VALIGN="top">Includes 28,881 Merger Closing Shares, 9,079 Merger Note Shares, 38,649 Milestone Shares and 20,224 Merger Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(9)</TD>
<TD ALIGN="left" VALIGN="top">Includes 51,564 Merger Closing Shares, 16,464 Merger Note Shares, 9,726 Milestone Shares and 36,675 Merger Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(10)</TD>
<TD ALIGN="left" VALIGN="top">Includes 168,907 Merger Closing Shares and 106,420 Milestone Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(11)</TD>
<TD ALIGN="left" VALIGN="top">Includes 7,945 Merger Closing Shares, 2,537 Merger Note Shares, 2,717 Milestone Shares and 5,651 Merger Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(12)</TD>
<TD ALIGN="left" VALIGN="top">Includes 7,945 Merger Closing Shares, 2,537 Merger Note Shares, 2,717 Milestone Shares and 5,651 Merger Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(13)</TD>
<TD ALIGN="left" VALIGN="top">Includes 11,445 Merger Closing Shares, 3,654 Merger Note Shares, 4,265 Milestone Shares and 8,140 Merger Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(14)</TD>
<TD ALIGN="left" VALIGN="top">Includes 11,445 Merger Closing Shares, 3,654 Merger Note Shares, 4,265 Milestone Shares and 8,140 Merger Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(15)</TD>
<TD ALIGN="left" VALIGN="top">Includes 20,124 Merger Closing Shares, 6,425 Merger Note Shares, 14,998 Milestone Shares and 14,313 Merger Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(16)</TD>
<TD ALIGN="left" VALIGN="top">Includes 1,567 Merger Closing Shares, 500 Merger Note Shares, 1,235 Milestone Shares and 1,114 Merger Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(17)</TD>
<TD ALIGN="left" VALIGN="top">Includes 427 Merger Closing Shares, 136 Merger Note Shares, 803 Milestone Shares and 303 Merger Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(18)</TD>
<TD ALIGN="left" VALIGN="top">Includes 590 Merger Closing Shares, 188 Merger Note Shares, 1,544 Milestone Shares and 419 Merger Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(19)</TD>
<TD ALIGN="left" VALIGN="top">Includes 448 Merger Closing Shares, 143 Merger Note Shares, 772 Milestone Shares and 318 Merger Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(20)</TD>
<TD ALIGN="left" VALIGN="top">Includes 237 Merger Closing Shares, 76 Merger Note Shares, 1,080 Milestone Shares and 168 Merger Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(21)</TD>
<TD ALIGN="left" VALIGN="top">Includes 2,222 Merger Closing Shares, 710 Merger Note Shares, 10,121 Milestone Shares and 1,580 Merger Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(22)</TD>
<TD ALIGN="left" VALIGN="top">Includes 25,058 Merger Closing Shares, 8,001 Merger Note Shares, 4,727 Milestone Shares and 17,823 Merger Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(23)</TD>
<TD ALIGN="left" VALIGN="top">Includes 12,529 Merger Closing Shares, 4,000 Merger Note Shares, 2,634 Milestone Shares and 8,911 Merger Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(24)</TD>
<TD ALIGN="left" VALIGN="top">Includes 62,647 Merger Closing Shares, 20,002 Merger Note Shares, 11,817 Milestone Shares and 44,558 Merger Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(25)</TD>
<TD ALIGN="left" VALIGN="top">Includes 12,529 Merger Closing Shares, 4,000 Merger Note Shares, 2,634 Milestone Shares and 8,911 Merger Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(26)</TD>
<TD ALIGN="left" VALIGN="top">Includes 112,765 Merger Closing Shares, 36,004 Merger Note Shares, 21,270 Milestone Shares and 80,204 Merger Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(27)</TD>
<TD ALIGN="left" VALIGN="top">Includes 300,000 Series B Conversion Preferred Shares and 255,000 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(28)</TD>
<TD ALIGN="left" VALIGN="top">Includes 405,400 shares of common stock issuable upon the exercise of warrants that have vested or will vest within 60 days of April&nbsp;11, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(29)</TD>
<TD ALIGN="left" VALIGN="top">Includes 371,635 Series B Conversion Preferred Shares and 315,890 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(30)</TD>
<TD ALIGN="left" VALIGN="top">Includes 1,111,112 Series B Conversion Preferred Shares and 944,445 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(31)</TD>
<TD ALIGN="left" VALIGN="top">Includes 952,381 Series B Conversion Preferred Shares and 809,524 Private Placement Warrant Shares. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(32)</TD>
<TD ALIGN="left" VALIGN="top">Includes 7,936,508 Series B Conversion Preferred Shares and 6,746,032 Private Placement Warrant Shares. Paul Segal is the manager of <FONT STYLE="white-space:nowrap">L-5</FONT> Healthcare Partners, LLC and accordingly
may be deemed to beneficially own the shares held by <FONT STYLE="white-space:nowrap">L-5</FONT> Healthcare Partners, LLC. Mr.&nbsp;Segal disclaims beneficial ownership of such shares except to the extent of his pecuniary interest in such shares.
</TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(33)</TD>
<TD ALIGN="left" VALIGN="top">Includes 500,000 shares of common stock issuable upon exercise of warrants that have vested or will vest within 60 days of April&nbsp;11, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(34)</TD>
<TD ALIGN="left" VALIGN="top">Includes 634,921 Series B Conversion Preferred Shares and 539,683 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(35)</TD>
<TD ALIGN="left" VALIGN="top">Includes 898,098 shares held by HealthpointCapital Partners, L.P. and 1,750,880 shares held by HealthpointCapital Partners II, L.P. Mr.&nbsp;Berkowitz is a managing member of HGP, LLC, which is the general partner of
HealthpointCapital Partners, L.P. and he is a managing member of HGP II, LLC, which is the general partner of HealthpointCapital Partners II, L.P., and therefore Mr.&nbsp;Berkowitz may be deemed to beneficially own the shares held by
HealthpointCapital Partners, L.P. and HealthpointCapital Partners II, L.P. Mr.&nbsp;Berkowitz disclaims beneficial ownership of such shares except to the extent of his pecuniary interest in such shares. Also includes 933 shares owned by
Mr.&nbsp;Berkowitz&#146;s spouse. Also includes 200,000 shares issuable upon the exercise of warrants that have vested or will vest within 60 days of April&nbsp;11, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(36)</TD>
<TD ALIGN="left" VALIGN="top">Includes 126,985 Series B Conversion Preferred Shares and 107,937 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(37)</TD>
<TD ALIGN="left" VALIGN="top">Mr.&nbsp;Berkowitz is the managing member of Porcupine Investment Partners, LLC and may therefore be deemed to beneficially own the shares held by Porcupine Investment Partners, LLC. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(38)</TD>
<TD ALIGN="left" VALIGN="top">Includes 200,000 shares issuable upon the exercise of warrants that have vested or will vest within 60 days of April&nbsp;11, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(39)</TD>
<TD ALIGN="left" VALIGN="top">Includes 126,985 Series B Conversion Preferred Shares and 107,937 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(40)</TD>
<TD ALIGN="left" VALIGN="top">Includes 250,000 shares of common stock held by MOM, LLC as well as 250,000 shares of common stock issuable upon the exercise of warrants held by MOM, LLC. Mr.&nbsp;Miles is the manager of MOM, LLC and therefore may be
deemed to beneficially own such shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(41)</TD>
<TD ALIGN="left" VALIGN="top">Includes 317,461 Series B Conversion Preferred Shares and 269,842 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(42)</TD>
<TD ALIGN="left" VALIGN="top">Includes 325,000 shares of common stock issuable upon exercise of options or warrants that have vested or will vest within 60 days of April&nbsp;11, 2018. Also includes 50,000 restricted stock units that will vest
within 60 days of April&nbsp;11, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(43)</TD>
<TD ALIGN="left" VALIGN="top">Includes 100,635 Series B Conversion Preferred Shares and 85,540 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(44)</TD>
<TD ALIGN="left" VALIGN="top">Includes 58,096 Series B Conversion Preferred Shares and 49,381 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(45)</TD>
<TD ALIGN="left" VALIGN="top">Includes 320,477 shares of common stock issuable upon exercise of options or warrants that have vested or will vest within 60 days of April&nbsp;11, 2018. Also includes 57,774 restricted stock units that will vest
within 60 days of April&nbsp;11, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(46)</TD>
<TD ALIGN="left" VALIGN="top">Includes 158,731 Series B Conversion Preferred Shares and 134,921 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(47)</TD>
<TD ALIGN="left" VALIGN="top">Includes 25,397 Series B Conversion Preferred Shares and 21,588 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(48)</TD>
<TD ALIGN="left" VALIGN="top">Includes 73,437 shares of common stock issuable upon exercise of options or warrants that have vested or will vest within 60 days of April&nbsp;11, 2018. Also includes 18,750 restricted stock units that will vest within
60 days of April&nbsp;11, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(49)</TD>
<TD ALIGN="left" VALIGN="top">Includes 31,747 Series B Conversion Preferred Shares and 26,985 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(50)</TD>
<TD ALIGN="left" VALIGN="top">Includes 15,874 Series B Conversion Preferred Shares and 13,493 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(51)</TD>
<TD ALIGN="left" VALIGN="top">Includes 4,062 shares of common stock issuable upon exercise of options that have vested or will vest within 60 days of April&nbsp;11, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(52)</TD>
<TD ALIGN="left" VALIGN="top">Includes 12,699 Series B Conversion Preferred Shares and 10,794 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(53)</TD>
<TD ALIGN="left" VALIGN="top">Includes 317,461 Series B Conversion Preferred Shares and 269,842 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(54)</TD>
<TD ALIGN="left" VALIGN="top">Includes 75,000 Series B Conversion Preferred Shares and 63,750 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(55)</TD>
<TD ALIGN="left" VALIGN="top">Includes 7,291 shares of common stock issuable upon exercise of options that have vested or will vest within 60 days of April&nbsp;11, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(56)</TD>
<TD ALIGN="left" VALIGN="top">Includes 13,334 Series B Conversion Preferred Shares and 11,334 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(57)</TD>
<TD ALIGN="left" VALIGN="top">Includes 48,437 shares of common stock issuable upon exercise of options or warrants that have vested or will vest within 60 days of April&nbsp;11, 2018. Also includes 18,750 restricted stock units that will vest within
60 days of April&nbsp;11, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(58)</TD>
<TD ALIGN="left" VALIGN="top">Includes 15,874 Series B Conversion Preferred Shares and 13,493 Private Placement Warrant Shares. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(59)</TD>
<TD ALIGN="left" VALIGN="top">Includes 153,125 shares of common stock issuable upon exercise of options or warrants that have vested or will vest within 60 days of April&nbsp;11, 2018. Also includes 18,750 restricted stock units that will vest
within 60 days of April&nbsp;11, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(60)</TD>
<TD ALIGN="left" VALIGN="top">Includes 15,874 Series B Conversion Preferred Shares and 13,493 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(61)</TD>
<TD ALIGN="left" VALIGN="top">Includes 79,366 Series B Conversion Preferred Shares and 67,461 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(62)</TD>
<TD ALIGN="left" VALIGN="top">Includes 20,000 shares of common stock issuable upon the exercise of warrants that have vested or will vest within 60 days of April&nbsp;11, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(63)</TD>
<TD ALIGN="left" VALIGN="top">Includes 39,683 Series B Conversion Preferred Shares and 33,731 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(64)</TD>
<TD ALIGN="left" VALIGN="top">Includes 31,747 Series B Conversion Preferred Shares and 26,985 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(65)</TD>
<TD ALIGN="left" VALIGN="top">Includes 31,747 Series B Conversion Preferred Shares and 26,985 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(66)</TD>
<TD ALIGN="left" VALIGN="top">Includes 100,000 shares of common stock issuable upon the exercise of warrants that have vested or will vest within 60 days of April&nbsp;11, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(67)</TD>
<TD ALIGN="left" VALIGN="top">Includes 160,000 Series B Conversion Preferred Shares and 136,000 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(68)</TD>
<TD ALIGN="left" VALIGN="top">Includes 160,000 Series B Conversion Preferred Shares and 136,000 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(69)</TD>
<TD ALIGN="left" VALIGN="top">Includes 15,874 Series B Conversion Preferred Shares and 13,493 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(70)</TD>
<TD ALIGN="left" VALIGN="top">Includes 55,000 Series B Conversion Preferred Shares and 46,750 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(71)</TD>
<TD ALIGN="left" VALIGN="top">Includes 111,112 Series B Conversion Preferred Shares and 94,445 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(72)</TD>
<TD ALIGN="left" VALIGN="top">Includes 125,000 shares of common stock issuable upon the exercise of warrants that have vested or will vest within 60 days of April&nbsp;11, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(73)</TD>
<TD ALIGN="left" VALIGN="top">Includes 126,985 Series B Conversion Preferred Shares and 107,937 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(74)</TD>
<TD ALIGN="left" VALIGN="top">Includes 100,000 shares of common stock issuable upon the exercise of warrants that have vested or will vest within 60 days of April&nbsp;11, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(75)</TD>
<TD ALIGN="left" VALIGN="top">Includes 79,366 Series B Conversion Preferred Shares and 67,461 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(76)</TD>
<TD ALIGN="left" VALIGN="top">Includes 28,572 Series B Conversion Preferred Shares and 24,286 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(77)</TD>
<TD ALIGN="left" VALIGN="top">Includes 63,493 Series B Conversion Preferred Shares and 53,969 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(78)</TD>
<TD ALIGN="left" VALIGN="top">Includes 100,000 shares of common stock issuable upon the exercise of warrants that have vested or will vest within 60 days of April&nbsp;11, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(79)</TD>
<TD ALIGN="left" VALIGN="top">Includes 95,239 Series B Conversion Preferred Shares and 80,953 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(80)</TD>
<TD ALIGN="left" VALIGN="top">Includes 100,000 shares of common stock issuable upon the exercise of warrants that have vested or will vest within 60 days of April&nbsp;11, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(81)</TD>
<TD ALIGN="left" VALIGN="top">Includes 103,175 Series B Conversion Preferred Shares and 87,699 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(82)</TD>
<TD ALIGN="left" VALIGN="top">Includes 38,700 shares of common stock issuable upon conversion of Series A Convertible Preferred Stock and 50,000 shares of common stock issuable upon exercises of warrants that have vested or will vest within 60 days
of April&nbsp;11, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(83)</TD>
<TD ALIGN="left" VALIGN="top">Includes 63,493 Series B Conversion Preferred Shares and 53,969 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(84)</TD>
<TD ALIGN="left" VALIGN="top">Includes 31,747 Series B Conversion Preferred Shares and 26,985 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(85)</TD>
<TD ALIGN="left" VALIGN="top">Includes 63,493 Series B Conversion Preferred Shares and 53,969 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(86)</TD>
<TD ALIGN="left" VALIGN="top">Includes 12,698 Series B Conversion Preferred Shares and 10,794 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(87)</TD>
<TD ALIGN="left" VALIGN="top">Includes 15,874 Series B Conversion Preferred Shares and 13,493 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(88)</TD>
<TD ALIGN="left" VALIGN="top">Includes 47,620 Series B Conversion Preferred Shares and 40,477 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(89)</TD>
<TD ALIGN="left" VALIGN="top">Includes 31,747 Series B Conversion Preferred Shares and 26,985 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(90)</TD>
<TD ALIGN="left" VALIGN="top">Includes 31,747 Series B Conversion Preferred Shares and 26,985 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(91)</TD>
<TD ALIGN="left" VALIGN="top">Includes 31,747 Series B Conversion Preferred Shares and 26,985 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(92)</TD>
<TD ALIGN="left" VALIGN="top">Includes 119,000 Series B Conversion Preferred Shares and 101,150 Private Placement Warrant Shares. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(93)</TD>
<TD ALIGN="left" VALIGN="top">Includes 1,857,586 shares of common stock issuable upon conversion of Series A Convertible Preferred Stock and 700,000 shares of common stock issuable upon exercises of warrants that have vested or will vest within 60
days of April&nbsp;11, 2018. </TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%" VALIGN="top" ALIGN="left">(94)</TD>
<TD ALIGN="left" VALIGN="top">Includes 1,800,000 New Warrant Shares. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each time a Selling Stockholder sells any securities
offered by this prospectus, the Selling Stockholder is required to provide you with this prospectus and, to the extent required, a related prospectus supplement </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
containing specific information about such Selling Stockholder and the terms of the securities being offered in the manner required by the Securities Act. Any prospectus supplement will, to the
extent required, set forth the following information with respect to the Selling Stockholder: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the name of the Selling Stockholder; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the nature of any position, office or other material relationship that the Selling Stockholder has had within the last three years with us, our predecessors or any of our affiliates; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amount of Common Stock owned by the Selling Stockholder prior to the offering; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amount of Common Stock to be offered for the Selling Stockholder&#146;s account; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amount and (if one percent or more) the percentage of Common Stock to be beneficially owned by the Selling Stockholder after the completion of the offering. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">No offer or sale may occur unless the registration statement that includes this prospectus has been declared effective by the SEC and remains effective at the
time a Selling Stockholder offers or sells Common Stock. We are required, under certain circumstances, to update, supplement or amend this prospectus to reflect material developments in our business, financial position and results of operations and
may do so by an amendment to this prospectus, a prospectus supplement or a future filing with the SEC incorporated by reference in this prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx571807_9"></A>DESCRIPTION OF CAPITAL STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following descriptions are summaries of material terms of our Common Stock, preferred stock, articles of incorporation and bylaws. This
summary is qualified by reference to our articles of incorporation, bylaws and the Series B Designation of Rights, which are filed or incorporated by reference as exhibits to the registration statement of which this prospectus forms a part, and by
the provisions of applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of April&nbsp;11, 2018, our authorized capital stock was as follows: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">200,000,000 shares of Common Stock, $0.0001 par value per share, of which 25,548,990 shares are issued and outstanding; and </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, as of April&nbsp;11, 2018: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">At least 14,349,236 shares of Common Stock were reserved for issuance pursuant to the conversion of our Series B Preferred Stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">At least 16,196,851 shares of Common Stock were reserved for issuance pursuant to the Warrants </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">At least 987,578 shares of Common stock were reserved for issuance pursuant to the Merger Notes; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">At least 1,330,263 shares of the Common Stock were reserved for issuance as Milestone Shares. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition to the descriptions set forth below, please refer to our other publicly filed documents incorporated herein by reference, which
describe our other outstanding preferred stock, warrants, registration rights, equity incentive plans and other securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Common Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to any special voting rights of any series of preferred stock that we may issue in the future, each share held of record of Common
Stock has one vote on all matters voted on by our stockholders, including the election of our directors. Because holders of Common Stock do not have cumulative voting rights, the holders of a majority of the shares of Common Stock can elect all of
the members of the Board of Directors standing for election, subject to the rights, powers and preferences of any outstanding series of preferred stock. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No share of Common Stock affords any preemptive rights or is convertible, redeemable, assessable or entitled to the benefits of any sinking or
repurchase fund. Holders of Common Stock will be entitled to dividends in the amounts and at the times declared by our Board of Directors in its discretion out of funds legally available for the payment of dividends. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of Common Stock are entitled to receive dividends when, as and if declared by the Board of Directors out of funds legally available
therefor, subject to any dividend preferences of any outstanding shares of preferred stock. Holders of Common Stock will share equally in our assets on liquidation after payment or provision for all liabilities and any preferential liquidation
rights of any preferred stock then outstanding. All outstanding shares of Common Stock are fully paid and <FONT STYLE="white-space:nowrap">non-assessable.</FONT> Our Common Stock is traded on Nasdaq under the symbol &#147;ATEC.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Stockholder Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Securities
Purchase Agreement <FONT STYLE="white-space:nowrap">provides&nbsp;L-5</FONT> Healthcare the right to appoint (i)&nbsp;up to two members of the Board of Directors of the Company (the &#147;<U>Board</U>&#148;) for so long as the <FONT
STYLE="white-space:nowrap">L-5</FONT> Group (as defined below) continues to hold collectively at least 12.5% of the Company&#146;s fully diluted Common Stock, and (ii)&nbsp;one member of the Board for so long as the
<FONT STYLE="white-space:nowrap">L-5</FONT> Group continues to hold collectively at least 7.5% of the Company&#146;s fully diluted </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
Common Stock but less than 12.5% of the Company&#146;s fully diluted Common Stock. The Securities Purchase Agreement also provides that one member of the Board appointed by <FONT
STYLE="white-space:nowrap">L-5</FONT> Healthcare, as applicable, shall be permitted to attend as an observer any meetings of traditional Board committees. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Additionally, pursuant to the terms of the Securities Purchase Agreement, the Company granted to <FONT STYLE="white-space:nowrap">L-5</FONT>
Healthcare and its affiliates and their respective members, stockholders, owners, equity holders and family members (collectively, the &#147;<U><FONT STYLE="white-space:nowrap">L-5</FONT> Group</U>&#148;), so long as the <FONT
STYLE="white-space:nowrap">L-5</FONT> Group continues to hold collectively at least 12.5% of the Company&#146;s fully diluted Common Stock, the right to purchase, on the terms and subject to the conditions set forth in the Securities Purchase
Agreement, each such stockholder&#146;s pro rata share of any shares of Common Stock or securities exercisable for or convertible into Common Stock issued by the Company, other than such securities issued in any exempt issuance specified in the
Securities Purchase Agreement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The transfer agent and registrar for our Common Stock is Computershare, Inc., with a mailing address of 480 Washington Ave., Jersey City, NJ
07310. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As of the
date of this prospectus, we have 20,000,000 shares of authorized preferred stock, of which 15,245 have been designation as Series A Preferred Stock, 4,044 of which are currently outstanding, and 45,200 have been designated as Series B Convertible
Preferred Stock, 45,200 of which are currently outstanding. At the direction of our Board of Directors, we may issue shares of preferred stock from time to time. Our Board of Directors may, without any action by holders of our Common Stock: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adopt resolutions to issue preferred stock in one or more classes or series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">fix the number of shares constituting any class or series of preferred stock; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">establish the rights of the holders of any class of preferred stock. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights of any class
or series of preferred stock may include, among others: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">general or special voting rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preferential liquidation or preemptive rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">preferential cumulative or noncumulative dividend rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">redemption or put rights; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">conversion or exchange rights. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue shares of, or rights to purchase, preferred
stock, the terms of which might: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">adversely affect voting or other rights evidenced by, or amounts otherwise payable with respect to, the Common Stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">discourage an unsolicited proposal to acquire us; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">facilitate a particular business combination involving us. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any of these actions could
discourage a transaction that some or a majority of our stockholders might believe to be in their best interests or in which our stockholders might receive a premium for their stock over its then market price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Series A Convertible Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the terms of the Series A Designation of Rights filed with the Secretary of State of the State of Delaware in
March 2017. A total of 15,245 shares of Series A Convertible Preferred Stock are authorized for issuance and a total of 4,043.3460 shares of Series A Convertible Preferred Stock are outstanding as of April&nbsp;11, 2018. The shares of Series A
Convertible Preferred Stock have a stated value of $1,000 per share and are convertible into shares of our common stock at an initial conversion price of $2.00 per share. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of the Series A Convertible Preferred Stock are entitled to dividends on an <FONT STYLE="white-space:nowrap">as-if</FONT> converted
basis in the same form as any dividends actually paid on shares of our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of Series A Convertible Preferred Stock
will be convertible, at the option of each holder, at any time or from time to time into shares of our common stock at the conversion price in effect at the time of conversion, except that, subject to certain limited exceptions, no holder of Series
A Convertible Preferred Stock may convert the Series A Convertible Preferred Stock if, after giving effect to the conversion, the holder and all affiliated persons would own beneficially more than 4.99% of our common stock (subject to adjustment up
to 9.99% solely at the holder&#146;s discretion upon 61 days&#146; prior notice to us). The initial conversion price of $2.00 is subject to appropriate adjustment in the event of a stock split, stock dividend, combination or other recapitalization
affecting our common stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise required by law, the holders of Series A Convertible Preferred Stock have no right to
vote on matters submitted to a vote of our stockholders. Without the affirmative vote of the holders of 75% of the outstanding shares of Series A Convertible Preferred Stock, however, we may not: (1)&nbsp;amend our restated certificate of
incorporation, as amended, (including the Certificate of Designation) in a manner adverse to the Series A Convertible Preferred Stock; (ii)&nbsp;increase the number of authorized shares of preferred stock, or (iii)&nbsp;enter into any agreement with
respect to any of the foregoing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of the dissolution and winding up of the Company, the proceeds available for distribution
to the Company&#146;s stockholders shall be distributed <I>pari passu</I> among the holders of the shares of Common Stock and Series A Convertible Preferred Stock, pro rata based upon the number of shares held by each such holder, as if the
outstanding shares of Series A Convertible Preferred Stock were convertible, and were converted, into shares of Common Stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Series B Convertible
Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following is a summary of the terms of the Series B Designation of Rights filed with the Secretary of State of the
State of Delaware on March&nbsp;8, 2018 in connection with closing the Private Placement. We encourage you to read the Series B Designation of Rights thoroughly; the following summary is qualified in its entirety by reference to the actual terms
contained in the Series B Designation of Rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A total of 45,200 shares of Series B Preferred Stock are authorized for issuance under
the Series B Designation of Rights. Each share of Series B Preferred Stock has a stated value of $1,000 and is convertible into approximately 317 shares of the Company&#146;s Common Stock at a conversion price per share of $3.15. Until the date that
Stockholder Approval is obtained, the Purchasers will be unable to convert their Series B Preferred Shares into Common Stock, in accordance with Nasdaq rules and regulations. Upon Stockholder Approval, the Series B Preferred Shares will
automatically convert into shares of Common Stock. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Series B Preferred Stock will be entitled to dividends on an <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">as-if-converted</FONT></FONT> basis in the same form as any dividends actually paid on shares of Common Stock or other securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The initial conversion price of $3.15 is subject to appropriate adjustment in the event of a stock split, stock dividend, combination,
reclassification or other recapitalization affecting the Common Stock. In addition, until </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
the earlier of the date there are no shares of Series B Preferred Stock outstanding, or one year from the effective date of the Resale Registration Statement, the conversion price is also subject
anti-dilution protection adjustment in the event the Company issues securities at an effective price less than the initial conversion price, subject to certain exceptions. If the Company&#146;s stockholders do not approve the conversion feature of
the Series B Preferred Stock, the shares of Series B Preferred Stock will not become convertible, and will remain outstanding in accordance with the terms of the Series B Designation of Rights. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise required by law, the holders of Series B Preferred Stock will have no right to vote on matters submitted to a vote of the
Company&#146;s stockholders. Without the prior written consent of 75% of the outstanding shares of Series B Preferred Stock, however, the Company may not: (a)&nbsp;alter or change adversely the powers, preferences or rights given to the Series B
Preferred Stock or alter or amend the Series B Designation of Rights; (b)&nbsp;amend the Company&#146;s certificate of incorporation or other charter documents in any manner that adversely affects any rights of the holders of Series B Preferred
Stock; (c)&nbsp;increase the number of authorized shares of Series B Preferred Stock; or (d)&nbsp;enter into any agreement with respect to any of the foregoing. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of the dissolution and winding up of the Company, the proceeds available for distribution to the Company&#146;s stockholders
shall be distributed <I>pari passu</I> among the holders of the shares of Common Stock and Series B Preferred Stock, pro rata based upon the number of shares held by each such holder, as if the outstanding shares of Series B Preferred Stock were
convertible, and were converted, into shares of Common Stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx571807_10"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As explained above under &#147;Selling Stockholders,&#148; in connection with the Merger, the Company granted to the former stockholders of
SafeOp the Merger Warrants, granted the Private Placement Warrants in connection with the Private Placement, and granted the New Warrants in connection with the Warrant Exercise Agreement. The Merger Warrants, Private Placement Warrants and New
Warrants are sometimes referred to collectively herein as the &#147;<U>Warrants</U>.&#148; Each Warrant may be exercised for the purchase of one share of Common Stock for $3.50 per share (subject to adjustment in the event of a stock split, stock
dividend, combination or other proportionate recapitalization). The Warrants may not be exercised until we have obtained Stockholder Approval. The Warrants are exercisable for cash for a term of five years from the date of Stockholder Approval.
Unless a holder elects otherwise, the holder of a Warrant is restricted from the exercise of the Warrant or any portion thereof held by such holder, to the extent that, after giving effect to the exercise, such holder (together with such
holder&#146;s affiliates, and any persons acting as a group together with such holder or any of such holder&#146;s affiliates) would beneficially own in excess of the Beneficial Ownership Limitation. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx571807_11"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are registering an aggregate of 36,129,060 shares of Common Stock held by or issuable to the Selling Stockholders identified in this
prospectus pursuant to registration rights granted to the Selling Stockholders under certain agreements. We are also registering an indeterminate number of shares of Common Stock that may be issued in the future pursuant to provisions of the
Securities Purchase Agreement, Series B Designation of Rights, and the Warrants to prevent dilution resulting from stock splits, stock dividends, dilutive issuances, or similar transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each Selling Stockholder of the securities and any of its pledgees, assignees and <FONT STYLE="white-space:nowrap"><FONT
STYLE="white-space:nowrap">successors-in-interest</FONT></FONT> may, from time to time, sell any or all of their securities covered hereby on Nasdaq or any other stock exchange, market or trading facility on which the securities are traded or in
private transactions. These sales may be at fixed or negotiated prices. A Selling Stockholder may use any one or more of the following methods when selling securities: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">ordinary brokerage transactions and transactions in which the broker-dealer solicits purchasers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">block trades in which the broker-dealer will attempt to sell the securities as agent but may position and resell a portion of the block as principal to facilitate the transaction; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">purchases by a broker-dealer as principal and resale by the broker-dealer for its account; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an exchange distribution in accordance with the rules of the applicable exchange; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">privately negotiated transactions; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">settlement of short sales; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">in transactions through broker-dealers that agree with the Selling Stockholders to sell a specified number of such securities at a stipulated price per security; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">through the writing or settlement of options or other hedging transactions, whether through an options exchange or otherwise; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a combination of any such methods of sale; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other method permitted pursuant to applicable law. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Stockholders may also sell
securities under Rule 144 or any other exemption from registration under the Securities Act, if available, rather than under this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Broker-dealers engaged by the Selling Stockholders may arrange for other broker-dealers to participate in sales. Broker-dealers may receive
commissions or discounts from the Selling Stockholders (or, if any broker-dealer acts as agent for the purchaser of securities, from the purchaser) in amounts to be negotiated, but, except as set forth in a supplement to this Prospectus, in the case
of an agency transaction not in excess of a customary brokerage commission in compliance with FINRA Rule 2440; and in the case of a principal transaction a markup or markdown in compliance with FINRA <FONT STYLE="white-space:nowrap">IM-2440.</FONT>
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with the sale of the securities or interests therein, the Selling Stockholders may enter into hedging transactions with
broker-dealers or other financial institutions, which may in turn engage in short sales of the securities in the course of hedging the positions they assume. The Selling Stockholders may also sell securities short and deliver these securities to
close out their short positions, or loan or pledge the securities to broker-dealers that in turn may sell these securities. The Selling Stockholders may also enter into option or other transactions with broker-dealers or other financial institutions
or create one or more derivative securities which require the delivery to such broker-dealer or other financial institution of securities offered by this prospectus, which securities such broker-dealer or other financial institution may resell
pursuant to this prospectus (as supplemented or amended to reflect such transaction). </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Selling Stockholders and any broker-dealers or agents that are involved in selling the
securities may be deemed to be &#147;underwriters&#148; within the meaning of the Securities Act in connection with such sales. In such event, any commissions received by such broker-dealers or agents and any profit on the resale of the securities
purchased by them may be deemed to be underwriting commissions or discounts under the Securities Act. Each Selling Stockholder has informed the Company that it does not have any written or oral agreement or understanding, directly or indirectly,
with any person to distribute the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The Company is required to pay certain fees and expenses incurred by the Company incident
to the registration of the securities. The Company has agreed to indemnify the Selling Stockholders against certain losses, claims, damages and liabilities, including liabilities under the Securities Act. The Company is also required to pay certain
fees and expenses in connection with any underwritten offering under the Registration Rights Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling Stockholders may be
subject to the prospectus delivery requirements of the Securities Act including Rule 172 thereunder. In addition, any securities covered by this prospectus which qualify for sale pursuant to Rule 144 under the Securities Act may be sold under Rule
144 rather than under this prospectus. The Selling Stockholders have advised us that there is no underwriter or coordinating broker acting in connection with the proposed sale of the resale securities by the Selling Stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We agreed to keep this prospectus effective until the earlier of the date on which (i)&nbsp;with respect to the Selling Stockholders other
than <FONT STYLE="white-space:nowrap">L-5</FONT> Healthcare, the securities may be resold by such Selling Stockholders without registration and without regard to any volume or
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">manner-of-sale</FONT></FONT> limitations by reason of Rule 144, without the requirement for the Company to be in compliance with the current public information under Rule 144 under
the Securities Act or any other rule of similar effect, (ii)&nbsp;the securities have been previously sold in accordance with Rule 144 or any other rule of similar effect and new certificates for them not bearing a legend restricting transfer shall
have been delivered by the Company or (iii)&nbsp;all of the securities have been sold pursuant to this prospectus. The resale securities will be sold only through registered or licensed brokers or dealers if required under applicable state
securities laws. In addition, in certain states, the resale securities covered hereby may not be sold unless they have been registered or qualified for sale in the applicable state or an exemption from the registration or qualification requirement
is available and is complied with. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under applicable rules and regulations under the Exchange Act, any person engaged in the distribution
of the resale securities may not simultaneously engage in market making activities with respect to the Common Stock for the applicable restricted period, as defined in Regulation M, prior to the commencement of the distribution. In addition, the
Selling Stockholders will be subject to applicable provisions of the Exchange Act and the rules and regulations thereunder, including Regulation M, which may limit the timing of purchases and sales of the Common Stock by the Selling Stockholders or
any other person. We will make copies of this prospectus available to the Selling Stockholders and have informed them of the need to deliver a copy of this prospectus to each purchaser at or prior to the time of the sale (including by compliance
with Rule 172 under the Securities Act). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will bear all costs, expenses and fees in connection with the registration of the shares of
Common Stock offered in this prospectus. The Selling Stockholders will bear any brokerage commissions and similar selling expenses that may result from their resale of the shares of Common Stock offered in this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Some of the underwriters, dealers or agents used by the Selling Stockholders in any offering of securities under this prospectus may be
customers of, engage in transactions with, and perform services for us and/or the Selling Stockholders, as applicable, or affiliates of ours and/or theirs, as applicable, in the ordinary course of business. Underwriters, dealers, agents and other
persons may be entitled under agreements which may be entered into with us and/or the Selling Stockholders to indemnification against and contribution toward certain civil liabilities, including liabilities under the Securities Act, and to be
reimbursed by us and/or such Selling Stockholders for certain expenses. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any securities initially sold outside the United States may be resold in the United States
through underwriters, dealers or otherwise. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any underwriters to which offered securities are sold by the Selling Stockholders for public
offering and sale may make a market in such securities, but those underwriters will not be obligated to do so and may discontinue any market making at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">To comply with the securities laws of some states, if applicable, the securities may be sold in jurisdictions only through registered or
licensed brokers or dealers. In addition, in some states the securities may not be sold unless they have been registered or qualified for sale or an exemption from registration or qualification requirements is available and is complied with. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx571807_12"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Durham Jones&nbsp;&amp; Pinegar, P.C., Salt Lake City, Utah, will pass upon the validity of the issuance of the securities to be offered by
this prospectus. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="supptx571807_13"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Ernst&nbsp;&amp; Young LLP, independent registered public accounting firm, has audited our consolidated financial statements as of
December&nbsp;31, 2016, and for the year ended December&nbsp;31, 2016 included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017, as set forth in the their report, which is
incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Ernst and Young LLP&#146;s report, given on their authority as experts in accounting and
auditing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Mayer Hoffman McCann P.C., independent registered public accounting firm, has audited our consolidated financial statements as
of December&nbsp;31, 2017, and for the year ended December&nbsp;31, 2017 included in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017, as set forth in their report, which is
incorporated by reference in this prospectus and elsewhere in the registration statement. Our financial statements are incorporated by reference in reliance on Mayer Hoffman McCann P.C.&#146;s report, given on their authority as experts in
accounting and auditing. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Nanavaty, Nanavaty&nbsp;&amp; Davenport, LLP, independent public accounting firm, has audited the consolidated
financial statements of SafeOP Surgical, Inc. as of and for the years ended December&nbsp;31, 2017 and 2016, as set forth in their reports, which are incorporated by reference in this prospectus and elsewhere in the registration statement. The
SafeOp Surgical, Inc. financial statements are incorporated by reference in reliance on Nanavaty, Nanavaty&nbsp;&amp; Davenport, LLP&#146;s reports, given on their authority as experts in auditing and accounting. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g571807g73t22.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g571807g73t22.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1B.4&AO=&]S:&]P(#,N,  X0DE-! 0
M     !\< 5H  QLE1QP!6@ #&R5'' %:  ,;)4<< @   @,^,3A"24T$)0
M    $,\_?\\#D7[VVY;>X-GX5<@X0DE-!#H      .4    0     0
M"W!R:6YT3W5T<'5T    !0    !0<W138F]O; $     26YT965N=6T
M26YT90    !#;')M    #W!R:6YT4VEX=&5E;D)I=&)O;VP     "W!R:6YT
M97).86UE5$585     $       ]P<FEN=%!R;V]F4V5T=7!/8FIC    # !0
M '( ;P!O &8 ( !3 &4 = !U '        IP<F]O9E-E='5P     0    !"
M;'1N96YU;0    QB=6EL=&EN4')O;V8    )<')O;V9#35E+ #A"24T$.P
M   "+0   !     !       2<')I;G1/=71P=71/<'1I;VYS    %P    !#
M<'1N8F]O;       0VQB<F)O;VP      %)G<TUB;V]L      !#<FY#8F]O
M;       0VYT0V)O;VP      $QB;'-B;V]L      !.9W1V8F]O;
M16UL1&)O;VP      $EN=')B;V]L      !"8VMG3V)J8P    $       !2
M1T)#     P    !29" @9&]U8D!OX            $=R;B!D;W5B0&_@
M        0FP@(&1O=6) ;^            !"<F1456YT1B-2;'0
M      !";&0@56YT1B-2;'0               !2<VQT56YT1B-0>&Q <L
M          IV96-T;W)$871A8F]O; $     4&=0<V5N=6T     4&=0<P
M  !09U!#     $QE9G15;G1&(U)L=                %1O<"!5;G1&(U)L
M=                %-C;"!5;G1&(U!R8T!9            $&-R;W!7:&5N
M4')I;G1I;F=B;V]L      YC<F]P4F5C=$)O='1O;6QO;F<         #&-R
M;W!296-T3&5F=&QO;F<         #6-R;W!296-T4FEG:'1L;VYG
M  MC<F]P4F5C=%1O<&QO;F<      #A"24T#[0      $ /      0 ! \
M   !  $X0DE-!"8       X             /X   #A"24T#\@      "@
M________   X0DE-! T       0    >.$))3009       $    'CA"24T#
M\P      "0           0 X0DE-)Q        H  0         ".$))30/U
M      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(
M   ! %H    &       ! #4    ! "T    &       !.$))30/X      !P
M  #_____________________________ ^@     ____________________
M_________P/H     /____________________________\#Z     #_____
M________________________ ^@  #A"24T$"       $     $   )    "
M0      X0DE-!!X       0     .$))300:      ,U    !@
M   !1P   PP          0                         !
M  ,,   !1P                     !                         !
M   !        ;G5L;     (    &8F]U;F1S3V)J8P    $       !28W0Q
M    !     !4;W @;&]N9P          3&5F=&QO;F<          $)T;VUL
M;VYG   !1P    !29VAT;&]N9P   PP    &<VQI8V5S5FQ,<P    %/8FIC
M     0      !7-L:6-E    $@    =S;&EC94E$;&]N9P         '9W)O
M=7!)1&QO;F<         !F]R:6=I;F5N=6T    ,15-L:6-E3W)I9VEN
M#6%U=&]'96YE<F%T960     5'EP965N=6T    *15-L:6-E5'EP90    !)
M;6<@    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO
M;F<          $QE9G1L;VYG          !"=&]M;&]N9P   4<     4F=H
M=&QO;F<   ,,     W5R;%1%6%0    !        ;G5L;%1%6%0    !
M    37-G951%6%0    !       &86QT5&%G5$585     $       YC96QL
M5&5X=$ES2%1-3&)O;VP!    "&-E;&Q497AT5$585     $       EH;W)Z
M06QI9VYE;G5M    #T53;&EC94AO<GI!;&EG;@    =D969A=6QT    "79E
M<G1!;&EG;F5N=6T    /15-L:6-E5F5R=$%L:6=N    !V1E9F%U;'0    +
M8F=#;VQO<E1Y<&5E;G5M    $453;&EC94)'0V]L;W)4>7!E     $YO;F4
M   )=&]P3W5T<V5T;&]N9P         *;&5F=$]U='-E=&QO;F<
M#&)O='1O;4]U='-E=&QO;F<         "W)I9VAT3W5T<V5T;&]N9P
M.$))300H       ,     C_P        .$))3001       ! 0 X0DE-!!0
M      0    '.$))300,      Y"     0   *    !#   !X   ?:    XF
M !@  ?_8_^T #$%D;V)E7T--  +_[@ .061O8F4 9(     !_]L A  ," @(
M"0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,#!$,# P,# P,# P,# P,
M# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.%!0.#@X.%!$,# P,#!$1
M# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,# P,# S_P  1" !# * #
M 2(  A$! Q$!_]T !  *_\0!/P   04! 0$! 0$          P ! @0%!@<(
M"0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)"@L0  $$ 0,"! (%!P8(
M!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D%5+!8C,T<H+10P<EDE/P
MX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-UX_-&)Y2DA;25Q-3D]*6U
MQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$  @(! @0$ P0%!@<'!@4U
M 0 "$0,A,1($05%A<2(3!3*!D12AL4(CP5+1\#,D8N%R@I)#4Q5C<S3Q)086
MHK*#!R8UPM)$DU2C%V1%539T9>+RLX3#TW7C\T:4I(6TE<34Y/2EM<75Y?56
M9G:&EJ:VQM;F]B<W1U=G=X>7I[?'_]H # ,!  (1 Q$ /P#B\O,RLW*MR\NU
M]U]SBZRQQ)))/ _=8WZ+&-^@A2?$_>D>2M'HG1W]4O?N<:L:F/5L;](D_1JJ
MGV[W?O\ ^#5B<XXXF4C48[L4I  DN=)\2E)\2NV9]7.AM:&_9 ^/SGOL)/Q]
MZE_S>Z'_ -PV?YUG_I14O])X?W9_9'_OV+[Q'L7AY/B4I/B?O7<?\WNA_P#<
M-G^=9_Z42_YO=#_[AL_SK/\ THE_I/#^[D^R'_?J^\1[%X>3XG[TI/B5V.7]
M5NEWUD8[3B6_FO87.;/_  E5CG[F_P!38]<?E578MEU-S=MU!<U[>1+?/\YK
ME8P<SCS7P6"-XR^9?#)&>WXK2?$I2?$_>NK^MWU<Z7T;H/1+\-COM&;+\F^Q
MQ<Y\UB[;M_FJV,<_VMJK7)J8&Q:\BEY/B?O2D^)3)(J7D^)^]*3XG[TR22EY
M/B?O2D^)3))*7D^)^]*3XE,DDI>3XG[T;$S,K"RJLO$M?3D4N#J[&$@@@\']
MYCOHV5N^F@)QR$E/_]#ANY77?5$ =(<1R[(LD_!M87(GE=?]4O\ D@_^&+/R
M5IOQ'^8_P@UL_P GU=E4^H]6P>FM'VEY-KA+*&#=8X?O;?S&?R[%2Z_U]O3@
M<;&(=F.$N<=6U _1<]OY]S_\%5_URS_A,WI_U8S,QQRNI6/H%IW.!]V0^?SK
M-_\ ,_\ 7-]G_!5JAAY:' ,N>7MXS\H_3R>7]5ACC%<4S4>G>2LCZWYSR?LU
M%5#.Q?-CORU5_P#12Q/K?F,L'VVIEU)^D:FEE@'[S1N=79_46U5]7>B5M ^R
MML/[UKG/)^]VW_-:LWKOU=Q:\5^9T]GI.I&ZVD$EKF#Z;Z]^YS+*_I_N;%/#
M)R,R,8Q&/%Z1*0_[OBE->)82>'AJ^KKY_4Z</IKNH,+;6N:TX_@]S_YG^S_A
M'_\ !L>N!R'6/999:2^RT.>Y[N7%V[<_^TY:.+]HZH,#HX);54^QVX=F./J/
M?_UFOU/2_P"-4OK7775U*VJIH977CU,8P<!K6;6M5CE<4<$SBWG,2R7_ *J$
MN#'_ (R_'$0/#U-G_!'RO:_7SIW4<[ZN_5X8.)=EFM@-@HK=86@TL +_ $P[
M:N)_YN?63_RHSO\ V'L_\BNP_P 8MEC/JY]7/3>]DL$['%L_H&?N%JX+U\C_
M $]T'0_I'_\ DU9A=?:SRJT8((D:@\*]TWH76NK#=TS!NRJY+?5:W;5(Y;]H
MM-=&[_KBT?J1]7*_K#UMN-D@_8,5GKY8&FX3LIQMS?H^L_\ G/\ @:K5I_6+
M_&'U.[)?A?5^QO3^E8TTTNI8S?8UGZ,/:Y[7MHH]GZO72RO]%_VW623=! '4
MN3D_4CZWXM?J6]*N+1SZ3JKG?]M8UMMO_06'P2T@AS26N:1!!'TFN:?<US5N
M87UX^MN%:+6=2LO (+JLD-M8X#\UTM%C-W_ VUO70_6NGI_UF^JM?URPZACY
MV.6U]0K&NX!PQ[&/VC](_'>ZNW'N_P"XG_@:L@BZU[*H'9X)&Q,3,SKC1@X]
MN7<!+JZ&.L<!^\_8#L;_ %U9Z'TF[K76,7I=+MAR7G?9^Y6T>I?9_6;6W]'_
M ,+L7;_6;ZUU?52/JU]5J*L=^.UKLK(<W?M>]H<UK6N_G\I]?IV77W>K_P"D
MD9:T!94!U+RK?J/]<',WCI-VWS?4#_F.NWJF.B9].?CX?5*+^FC)<6,MMJD2
M!RS>^FJUK?;ZFR_]&KCOKO\ 6]S]YZM=N\ VH#_,;3M5/J_7NK]<=2[JN1]I
M=C-<VH[&L@/+7/W,J:RO<[8S\Q(<76E:(\GI]=&)7E,RJ[_5]$BEH(L:+JG9
M/Z=LGTG5N;Z/_"_SJJ#D)H'A_J4XY"<A_]'ACR5O]-ZLWI?U;-H@Y%N1:W':
M[42!7OM?_P '3_Z3K6 >2MGZL8 S<OUK_=1@0YC#P;;#O;N_J^GZO_;2?S0A
M[7%DUA B<A^_7RP_PIL&0#AN6P-NE]7^AFF.I=0!?FV'U*V6:EF[W>M;/_:J
MS_V7_P"-_F]U+G4ZI+$RY999F<OH.D8_NQ:DI&1LJ5+K&=5@=/MML <ZQIJJ
MK_?>\%NW^HUOOL_D(V;FXN!CG(RG[*QHT#5SW?Z.IGY[UR8.=]9>J1&QC&DM
M:-6U5_FM_EW7V;6;O\(__@JE+RO+\9]R?IPX_5*1Z\/Z(78X7ZCI$;EN?4S&
M;NRLDZNK:RAOP=-EA_M;*U0^MW_*V1_Q%?\ U"T/J7<",RDZ.(JMCX;ZW_\
M?%G_ %N_Y6R/^(K_ .H*OPO_ $AEO_-Z?^-,P_GI>3UG^,?_ ,3OU;_J#_SP
MQ< N_P#\8_\ XG/JW_5'_GABX!7(?+]K/+=] _Q9EV/T/ZQ9M<^JQH#8Y_14
MV6L_Z5J\^J98*F#TWZ-'YCO#^JO1/\5QMMZ/U_$QW%F0=KJGM,.#K*GUU.:[
M]YKZEQ=?UF^LKJVD]7SI+1/Z=_A_60'S2^BCL&CM?_HW_P"8[_R*[WZIM_\
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ME$2!!ZOI3@6-+G^QHY<[V@?%SO:L3J/UIPL8&O#C,OXW D4M/\JW_"_U:?\
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MW-]/UOLOO^E_I?U7_N3^B7+)('8^2AN__]DX0DE-!"$      %4    ! 0
M  \ 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '     3 $$ 9 !O &(
M90 @ %  : !O '0 ;P!S &@ ;P!P "  0P!3 #8    ! #A"24T$(@     !
M+DU- "H    (  <!$@ #     0 !   !&@ %     0   &(!&P %     0
M &H!*  #     0 "   !,0 "    '@   '(!,@ "    %    )"':0 $
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M          #_X0$P34T *@    @ !P$2  ,    !      $:  4    !
M8@$;  4    !    :@$H  ,    !  (   $Q  (    >    <@$R  (    4
M    D(=I  0    !    I    -    /      0   \     !061O8F4@4&AO
M=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.#HP-3HQ,B Q-SHR-3HP.0   Z !
M  ,    !__\  * "  0    !   ##* #  0    !   !1P         & 0,
M P    $ !@   1H !0    $   $> 1L !0    $   $F 2@  P    $  @
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M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!_]L
M0P$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$!_\  $0@ :0#Z P$1  (1 0,1 ?_$ !\
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M\^>MAPF/0[7!(=F)IZ:4<8;CJ-[$ L[@5]=:L<.6GJ,K&KC*ITG2-452=L(
MN2FZ?EIPZ!A .Z"Y8MHZ,E<#%MWP#<HCO;$7F6=Y+DX2O-\XRO*1%'N',LQE
M)$+22Q,,S4:$%U!JDD7:SXQX\W*2K?2IJ6EPW,#,1X4N"SM6*M -C9[5L0'7
M]P[.T1UR<S7TV_UNJP\;?[S6'IL'PQ$_AWP*!3C/A*M_^D>4='_QQQO<^>,3
M[]9.:G.,KI;_ )QDM'T\:NU@^#[AV=NH?<=S6Y_\7586_P#!OB&WPO?!^'G
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M6=B'K?9CO7L"QTJV*G9P6I;=QM3N0XUH^$M80Y]?#40'2VUM^5^>&[@Z;=:
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M1P4J:Y6LG*.GK<JY"'5(FL5)8@*%(HH4# (%.</>&?AI4B&A);W$)!(JRDI
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MYN;*OHL-?*SE*IB+]90*W<(2[K4D\Q)8$$'$M/3AEDI1##Q5@D4<(2-6U+T
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MR95%%2AW3@H&.<\7Q_$GX$$?5@2P+;+BK45:FZ4HO7&P96CEEU*-UQ"7U8
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MW27V:>B<!!!U++ 1=.G88YP&\G()"=<A%PBV4FX04;AU/V;>R/BKVE3B?O;
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MH\0$VYBJ#XBAH(B7OC 7M89EH\SXHB(;K)J.(7*Z/,^ AN\+=Q)U-4RZ398
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MHPU^ZH)B1(2B#]8!<,PXB7UY5(<$BJ20<FPXX.+ H%*7.RI@*  4H%84P!;
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M ?\ 7MWK=GTL$OI?WN>NH &HV 1YW'?SWPVJWNZ4H2:!R!HPMVMA/1_>UK4
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MZ -[ZZX79K%R#M6]ZT%2&:E,/N]PP(WI:U*F@+O6N$UY?]G8 W$>73K:P\Q
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9Q7-_V9^6,J2_A,+_ $A\\>J7CDN-FQ__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
